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GENERAL REMARKS 
 
1. Melting points were recorded by open capillary method and are uncorrected. 
2. Infrared spectra were recorded on Shimadzu FT IR-8400 (Diffuse reflectance
 attachment) using KBr. Spectra were calibrated against the polystyrene
 absorption at 1610 cm-1. 
3. 1H & 13C NMR spectra were recorded on Bruker Avance II 400 spectrometer.
 Sample Solution ware prepared in DMSO-d6 and CDCl3 solvents and
 tetramethylsilane (TMS) as a internal standard.  
4. Mass spectra were recorded on Shimadzu GC MS-QP 2010 spectrometer
 operating at 70 eV using direct injection probe technique. 
5. Analytical thin layer chromatography (TLC) was performed on Merck
 precoated silica gel-G F254 aluminium plates. Visualization of the spots on
 TLC plates was achieved either by exposure to iodine vapor or UV light. 
6. The chemicals used for the synthesis of intermediates and end products were
 purchased from Spectrochem, Sisco Research Laboratories (SRL), Thomas
 Baker, Sd fine chemicals, Loba chemie and SU-Lab. 
7. All the reactions were carried out in Samsung MW83Y microwave oven
 which was locally modified for carrying out chemical reactions 
8. Evaporation of all the solvents was carried out under reduced pressure on
 Heidolph LABOROTA-400-efficient. 
9. % Yield reported are isolated yields of material judged homogeneous by TLC
 and before recrystallization. 
10. The structures and names of all compounds are given in the experimental    
section and physical data table were generated using ChemBio Draw Ultra 
12.0. 
11. Elemental analysis was carried out on Vario EL Carlo Erba 1108. 
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ABBREVIATIONS 
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PAF Anti platelet activating factor 
AIDS Acquired immuno deficiency syndrome 
AlCl3 Aluminum chloride 
Ar Aromatic 
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µm Micro meter 
PPO Polyphenol oxidase 
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Chapter-1 
 
SYNTHESIS AND CHARACTERIZATION OF 4-
AMINO COUMARIN DERIVATIVES USING 
MICROWAVE IRRADIATION 
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1.1 INTRODUCTION 
 
Coumarin are the best known aromatic lactones.1The isolation of coumarin was first 
reported by Vogel2 in Munich in1820.He associated the pleasant odor of the tonka 
bean from Guiana with that of clover, Melilotous officinalis, which gives rise to the 
characteristic aroma of new -mown hay. Vogel then concluded that the long colorless 
crystals which he discovered on slicing open Tonka beans and which crystallized as 
glistening needles from aqueous alcohol were identical with similar crystals he 
obtained, albeit in much lower yield, by extracting fresh clover blossoms.3 The name 
coumarin originated4 from a Caribbean word ‘coumarou’ for the tonka tree, which 
was known botanically at one time as Coumarouna odorata aubl. Coumarin is now 
well, accepted trivial name. The IUPAC nomenclature of the coumarin ring system is 
2H-1-benzopyran-2-one (I) (Figure-1). 
 
Figure-1 
The coumarin ring system has an easy acceptability in the biological system compared 
to its isomeric chromones and flavones nucleus5 and is widely distributed in 
nature.6,9An excellent account of these naturally occurring coumarin is presented by 
Murray and Brown10 
 
Coumarin comprises a group of natural compounds found in a variety of plant 
sources. The very long association of plant coumarin with various animal species and 
other organisms throughout evolution may account for the extraordinary range of 
biochemical and pharmacological activities of these chemicals in mammalian and 
other biological systems. The coumarins that were studied have diverse biological 
properties and various effects on the different cellular systems. A lot of biological 
parameters should be evaluated to increase our understanding of mechanisms by 
which these coumarin act. Coumarin has important effects in plant biochemistry and 
physiology, acting as antioxidants, enzyme inhibitors and precursors of toxic 
substances. In addition, these compounds are involved in the actions of plant growth 
hormones and growth regulators, the control of respiration, photosynthesis, as well as 
defense against infection. The coumarins have long been recognized to possess anti-
inflammatory, antioxidant, antiallergic, hepatoprotective, antithrombotic, antiviral, 
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and anticarcinogenic activities. The hydroxycoumarins are typical phenolic 
compounds and, therefore, act as potent metal chelators and free radical scavengers. 
They are powerful chain-breaking antioxidants. The coumarin displays a remarkable 
array of biochemical and pharmacological actions, some of which suggest that certain 
members of this group of compounds may significantly affect the function of various 
mammalian cellular systems. The coumarins are extremely variable in structure, due 
to the various types of substitutions in their basic structure, which can influence their 
biological activity. Vast majority of coumarin, completely innocuous, may be 
beneficial in a variety of human disorders, in spite of some ongoing controversy. 
There has been, in recent years, a major rekindling of interest in pharmacognosy. 
Coumarin turns out to be present in many natural therapeutically utilized products. 
They hold a place apart in view of their cytotoxic activity. It was suggested that 
alterations in the chemical structure of coumarin could change their cytotoxic 
properties.11 
 
Coumarin and its derivatives have been prominently accepted as natural 
pharmaceuticals12 worldwide, has revealed new biological activities with interesting 
therapeutic applications, besides their traditional employment as anticoagulants(anti-
vitamin K activity),13antibiotics (novobiocin and analogues)14 and anti AIDS.15 Apart 
from this, they also possess anti-cancerous,11 antibacterial,16 neurotropic, 
17immunosuppressive,18 anti inflammatory,19 antiulcerous,20 anti PAF (anti platelet 
activating factor)21 and antimutagenic22 effects. 
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1.2 PHARMACOLOGY 
 
Numerous biological activities have been associated with simple coumarin and its 
analogues. Among them, antimicrobial, antiviral, anticancer, enzyme inhibition, anti-
inflammatory, antioxidant, anticoagulant and effect on central nervous system are 
most prominent. Coumarin nucleus possesses diversified biological activities that can 
be briefly summarized as under: 
 
1 Antimicrobial and Molluscicidal 23-45 
2 Antiviral 46-50 
3 Anticancer 51-61 
4 As Enzyme Inhibition 62-67 
5 Antioxidant 68-71 
6 Anti-inflammatory 72-76 
7 Anticoagulant and Cardiovascular 77-80 
8 Effect on Central Nervous System 81-82 
 
 
4-Hydroxycoumarin is a versatile scaffold and is being consistently used as a building 
block in organic chemistry as well as in heterocyclic chemistry for the synthesis of 
different heterocyclic compounds. The synthetic versatility of 4-hydroxy coumarin 
has led to the extensive use of this compound in organic synthesis. 4-hydroxy 
coumarin shows diversified chemical reactivity. 
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Amide linkage containing analogues: A collection of commercial 
analogues based on α-aminoamide structure83: (-NH-CO-CH2-N<) 
 
Lidofenin 
 
Butanilicain 
 
Bupivacaine 
 
 
Tylocain 
 
Aptocaine 
 
Trimecain 
 
Prilocaine 
 
Articain 
 
Pyrrocaine 
 
Mepivacaine 
 
Quatacaine 
 
Tocainidin 
 
Figure-2 
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1.3  SYNTHETIC ASPECT 
 
Coumarin and its derivatives were synthesized by many researchers using different 
methods.  
Perkin84 synthesized coumarin and then several methods are reported for the synthesis 
of 4-hydroxy coumarins and their 4-hydroxy substituted derivatives namely: 
 
1 Anschutz method 85 
2 Pauli Lockemann synthesis 86 
3 Sonn's synthesis 87 
4 Mentzer's synthesis 88 
5 Robertson synthesis 89 
6 Ziegler and Junek method 90 
7 Garden's method 91 
8 Shah, Bose and Shah's method 92 
9 Kaneyuki method 93 
10 Resplandy's method 94 
11 Jain, Rohatagi and Sheshadri's method 95 
12 Shah, Bhatt and Thakor's method 96 
 
Shah et al92-96 have prepared 4-hydroxy coumarin derivatives in good yield by 
condensation of different phenols with malonic acid in the presence of zinc chloride 
and phosphorous oxychloride. The method is useful as single step preparation of 4-
hydroxy coumarin derivatives substituted in benzenoid part. 
 
Pechmann Coumarin Synthesis 
 
Recently many researchers97-128 have reported synthetic strategies for 4-hydroxy 
coumarin. 
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The employment of hydrophobic ionic liquids dramatically enhanced the activity of 
metal triflates in Friedel-Crafts alkenylations of aromatic compounds with various 
alkyl-and aryl-substitutedalkynes.129 
 
COOMe
OMOM
R (OH)2B-Ar
1) 2-10% mol -CuOAc
MeOH, 280C, 6hr
3.0 eq 2) MeOH / 6M aq. HCl
(5:4), Ref , 3hr
O O
Ar
R
R: H, OH
OMe
 
Arylpropionic acid methyl esters having a MOM-protected hydroxy group at the 
ortho position underwent hydroarylation with various arylboronic acids in MeOH at 
ambient temperature in the presence of a catalytic amount of CuOAc, resulting in the 
formation of 4-arylcoumarins in high yields after the acidic workup.130 
 
 
 
The basic ionic liquid 1-butyl-3-methylimidazolium hydroxide, [bmim]OH, 
efficiently catalyzes the Knoevenagel condensation of various aliphatic and aromatic 
aldehydes and ketones with active methylenes at room temperature without 
requirement of any organic solvent.131 
 
 
 
A facile, convenient, efficient and high yielding synthesis of a combinatorial library 
of 3-aroylcoumarins has been developed by the condensation of easily available 
aroylketene dithioacetals and 2-hydroxybenzaldehydes in the presence of catalytic 
amount of piperidine in THF reflux.132 
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The ionic liquid 1-butyl-3-methylimidazonium tetrafluoroborate [bmim]BF4 was used 
for ethylenediammonium diacetate (EDDA) catalyzed Knoevenagel condensation 
between aldehydes or ketones with active methylene compounds. Catalyst and solvent 
were recyclable.133 
 
 
 
Zagorevskii, V. A. and Dudykina, N. V. was prepared 4-aminocoumarin from 4-
chlorocooumarin using liq. Ammonia and copper.134 
 
 
 
3-(2-Hydroxyphenyl)-3-iminopropanamide treated with 5% HCl at room temperature 
for 3 hours to yield 4-aminocoumarin.135 
 
 
 
Ivanov, I. et al reports the amination of 4-hydroxycoumarin using ammonium acetate 
as a catalyst.136,137 
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1.4  AIM OF CURRENT WORK 
 
The literature survey revealed that some extensive work has been done on coumarin 
compounds. Also, due to the usefulness of traditional medicines like Auraptene, 
Ferulenol and Fraxetin, the coumarin moiety has been selected for the research 
criteria. 
 
Anti-Tubercular drug in market 
 
 
Browsing through the literature of organomedicinal chemistry the most useful moiety 
found was substituted 4-amino coumarin derivatives. Because of the less toxicological 
properties and good to moderate activities, several compounds have been synthesized 
by our team in the laboratory which is given as under. The work encompassed in this 
chapter is an extension of the aforesaid research activity.   
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Anti-Tubercular compounds synthesized from our laboratory 
 
Though the chemistry of the synthesized compounds is unknown, the compounds are 
reported here in the first time. Biological importance of such vital compounds is 
described in chapter-5. 
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1.5  REACTION SCHEME 
 
 
 
a) Ammonium acetate, MW, 300W, 3.5min  
b) DMF,TEA, ClCH2COCl, 0-5 °C 
c) DMF, K2CO3, R1= Substituted amine 
 
1.6  PLAUSIBLE REACTION MECHANISM 
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1.7  EXPERIMENTAL 
 Preparation of 4-Amino coumarin 
A mixture of 4-hydroxy coumarin (0.1 mole ) and ammonium acetate (0.3 mole) was 
heated on microwave at 300 W, 100 °C for 3.5min. The reaction mixture was poured 
in ice, forming solid yellow product. This product was washed with sat. NaHCO3 to 
remove unreacted 4-hydroxy coumarin. The purity of the compound was checked by 
TLC. (EtoAC: Hexane :: 3:7). Yield : 80% 
 Preparation of 2-Chloro-N-(2-oxo-2H-chromen-4-yl)acetamide 
4-Amino coumarin (0.1 mole), Tri ethyl amine (0.2 mole) and DMF were taken in a 
flask and stirred it. Resulting mixture was cooled at 0-5 °C then added drop wise 
chloracetylchloride (0.2 mole). The reaction mixture was stirred for over night. The 
reaction was poured into the ice and extracted with ethyl acetate. The organic layer 
was separated out, dried with sodium sulphate and evaporated under vaccum to give 
yellow oily compound. The compound was purified by column chromatography by 
silica gel 230-400 mash. TLC. (EtoAC: Hexane :: 3:7). Yield : 65% 
Note: The entire reaction was carried out under nitrogen atmosphere. 
 General method for preparation of N-(2-oxo-2H-chromen-4-yl)-2-
(substituted amine -1-yl)acetamide derivatives 
2-Chloro-N-(2-oxo-2H-chromen-4-yl)acetamide (0.1 mole), anhydrous potassium 
carbonate (0.2 mole) and DMF were taken in flask and stirred continuously with 
mechanical stirring then added dropwise substituted amine (0.1 mole) at room 
temperature, reaction mixture was stirred for 12 h. The reaction was poured into the 
ice to give solid title compound.The compound was recrystlized by ethanol. TLC. 
(EtoAC: Hexane :: 4:6). Yield : 45-85% 
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1.8  PHYSICAL DATA  
TABLE: 1  PHYSICAL DATA OF N-(2-OXO-2H-CHROMEN-4-YL)-2-
(SUBSTITUTED AMINE -1-YL)ACETAMIDE DERIVATIVES 
Sr. 
No Code Structure M.F. 
M. P. 
(°C) 
Rf 
value 
% 
Yield 
1 DPB-1 
O O
HN O
N
C16H18N2O3 210-212 0.44 62 
2 DPB-2 C15H16N2O4 180-182 0.51 75 
3 DPB-3 C15H17N3O3 170-172 0.42 55 
4 DPB-4 C16H19N3O3 150-152 0.46 77 
5 DPB-5 C17H21N3O3 220-222 0.41 81 
6 DPB-6 C22H23N3O3 240-242 0.44 85 
7 DPB-7 C21H21N3O3 178-180 0.52 86 
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8 DPB-8 C15H16N2O3 168-170 0.42 65 
9 DPB-9 C23H18N2O3 154-156 0.45 74 
10 DPB-10 C15H18N2O3 176-178 0.48 56 
11 DPB-11 C17H20N2O3 188-190 0.51 62 
12 DPB-12 C17H13N2O3Cl 192-194 0.40 58 
13 DPB-13 C17H13N2O3Cl 160-162 0.44 52 
14 DPB-14 C18H16N2O3 188-190 0.40 61 
15 DPB-15 C18H16N2O3 179-181 0.50 63 
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16 DPB-16 C17H13N3O5 220-222 0.44 45 
17 DPB-17 C17H13N3O5 244-246 0.48 48 
18 DPB-18 C18H16N2O4 210-212 0.41 69 
19 DPB-19 C18H16N2O4 220-222 0.48 73 
20 DPB-20 C17H13N2O3F 240-242 0.44 66 
21 DPB-21 C17H12N2O3FCl 176-178 0.46 59 
22 DPB-22 C18H13N2O3F3 164-166 0.44 54 
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23 DPB-23 C19H18N2O3 174-176 0.42 68 
24 DPB-24 C18H16N2O3 184-186 0.48 42 
25 DPB-25 C17H20N2O3 220-222 0.42 47 
26 DPB-26 C17H14N2O3 236-238 0.51 62 
 
Rf value was calculated using solvent system, Ethyl acetate: Hexane (4: 6) 
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1.9  SPECTRAL STUDY 
 IR spectra 
Infra Red spectra were taken on Shimadzu FT-IR-8400 spectrometer using KBr 
Pellet method. The characteristic carbonyl group in coumarin moiety is observed at 
1750-1720 cm-1, while carbonyl value of –CONH peaks are observed in the range 
1690-1630 cm-1. Amine (> NH) observed a broad peak between 3200-3000 cm-
1.Methylene gp (-CH2) observed at 3000-2850 cm-1 and methyl (-CH3) observed at 
1350 cm-1. DPB-05 and DPB-20 of IR spectra are given on page no: - 32. 
 1H NMR spectra 
1H NMR spectra were recorded on a Bruker AC 400 MHz NMR spectrometer using 
TMS (Tetramethyl Silane) as an internal standard and DMSO-d6 & CDCl3 as a 
solvent. In the NMR spectra of N-(2-oxo-2H-chromen-4-yl)-2-(substituted amine-1-
yl)acetamide various proton values of methylene (-CH2), amine (>NH), methyl (-CH3) 
and aromatic protons (Ar-H) etc. were observed as under. 
The values for methylene (-CH2) proton is observed between 2.50-3.55 δ ppm. In 
some cases, the value of methylene proton differs 4.20-4.43 δ ppm. The -NH protons 
of substituted aniline was observed at 3.95-4.20 δ ppm. Aromatic protons shows the 
multiplet between  6.01-8.54 δ ppm. The signal due to NH proton of amide group 
(>CONH) was observed at  10.1-10.5 δ ppm value. DPB-02, DPB-05 and DPB-06 of 
1H NMR spectra are given on page no: - 27 to 31. 
 
1. The aromatic ring, in coumarin ring proton no. 1, 2, 3 and 4 are on same 
atmosphere so these four protons gave a multiplet at 7.42 δ ppm-7.67 δ ppm it 
shows in spectra. 
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2. The deshielded proton no. 5 of coumarin ring gave a singlet and it shows on 
down field at 7.56 δ ppm due to the effect of carbonyl group. 
3. The aromatic ring of the phenyl ring attached with methylene, in phenyl ring 
proton no. 11, 12, 15 and 16 are on same atmosphere so these five protons 
gave a multiplet at 7.26 δ ppm-7.41 δ ppm it shows in spectra. 
4. The proton no. 6 of the -NH (-CONH) group gave a characteristic broad 
singlet at 10.4 δ ppm. 
5. The proton no. 7 of the methylene group gave a characteristic singlet at 3.29 δ 
ppm. 
6. The proton no. 8 of four protons gave a multiplet at 2.74 δ ppm due to the 
effect of nitrogen atom. 
7. The proton no. 9 of four protons gave a multiplet at 2.90 δ ppm due to the 
effect of nitrogen atom. 
8. The proton no. 10 of the methylene group gave a characteristic singlet at 3.60 
δ ppm. 
 
Thus, by observing and assigning the peaks in the NMR spectrum and by the 
calculation of the J values for each of the above proton, the proposed structure for 
compound DPB-06 was confirmed.  
 13C NMR spectra 
13C NMR spectra were recorded on a Bruker AC 400 MHz NMR spectrometer using 
DMSO-d6 & CDCl3 as a solvent. In the 13C NMR spectra of N-(2-oxo-2H-chromen-4-
yl)-2-(substituted amine-1-yl)acetamide various carbon values of methylene (-CH2), 
keto (>C=O), methyl (-CH3) and aromatic carbon (Ar-H) etc. were observed as under. 
The values for methylene (-CH2) carbon is observed between 35-65 δ ppm. The 
>C=O carban observed at 160-180 δ ppm. Aromatic carbon shows between  110-140 
δ ppm. DPB-02, DPB-05 and DPB-06 of 13C NMR spectra are given on page no: - 27 
to 31. 
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1. The carbon no. 8, 9, 17 and 18 of piperazine ring, appear at 39.30 δ ppm-40.56 
δ ppm it shows in spectra. 
2. The carbon no. 7 of methylene group, appear at 53.36 δ ppm due to the effect 
of nitrogen atom. 
3. The carbon no. 10 of methylene group, appear at 62.66 δ ppm due to the effect 
of nitrogen atom. 
4. The carbon no. 20 of coumarin ring, appear at 99.36 δ ppm due to the effect of 
carbonyl group. 
5. The carbon no. 5 of coumarin ring, appear at 114.05 δ ppm  
6. The carbon no. 1,2,3,4,11,12,13,14,15,16 and 22 of aromatic, appear at 114.05 
δ ppm-144.74 δ ppm. 
7. The carbon no. 21 of coumarin ring, appear at 153.71 δ ppm due to the effect 
of carbonyl group. 
8. The carbon no. 6 of coumarin ring, appear at 161.92 δ ppm due to the effect of 
carbonyl group. 
9. The carbon no. 19 of coumarin ring, appear at 169.89 δ ppm due to the effect 
of nitrogen atom. 
 
 Mass spectra 
The mass spectrum of compounds were recorded by Shimadzu GC-MS-QP-2010 
spectrometer. The mass spectrum of compounds was obtained by positive chemical 
ionization mass spectrometry. The molecular ion peak and the base peak in all 
compounds were clearly obtained in mass spectral study. The molecular ion peak 
(M+) values are in good agreement with molecular formula of all the compounds 
synthesized. DPB- 19, DPB-20 and DPB-22 of Mass spectra are given on page no.- 
26 and 27. 
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 Elemental analysis 
Elemental analysis of the synthesized compounds was carried out on Vario EL-III 
Carlo Erba 1108 model at Saurashtra University, Rajkot which showed that 
calculated and found percentage values of Carbon, Hydrogen and Nitrogen in support 
of the structure of synthesized compounds. The elemental analysis data are given for 
individual compounds. 
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1.10  SPECTRAL CHARACTERIZATION 
N-(2-oxo-2H-chromen-4-yl)-2-(piperidin-1-yl)acetamide  (DPB-1) 
IR (KBr) cm-1: 3355 (-NH), 1285 (C-N, str), 1714 (>C=O), 1680 (-CONH), 2869 
(>CH2 ,str), 1450 (>CH2 ,ban), 3010 (-CH, str), 3052 (Ar, C-H, str), 1523 (Ar, C=C, 
str). Mass: [m/e (%)], M. Wt.: 286. Elemental analysis, Calculated: C, 67.12; H, 
6.34; N, 9.78 Found: C, 67.04; H, 6.30; N, 9.72. 
 2-Morpholino-N-(2-oxo-2H-chromen-4-yl)acetamide (DPB-2) 
IR (KBr) cm-1: 3368 (-NH), 1280 (C-N, str), 1710 (>C=O), 1650 (-CONH), 2850 
(>CH2 ,str), 1390 (>CH2 ,ban), 3075 (-CH, str), 3050 (Ar, C-H, str), 1510 (Ar, C=C, 
str), 1120 (C-O-C). 1H NMR 400 MHz: (DMSO-d6, δ ppm): 2.59 (m, 4H, -CH2), 
3.32 (s, 2H, -CH2), 3.84 (m, 4H, -CH2), 7.37-7.67 (m, 5H, Ar-H), 10.23 (s, broad, 
1H,-NH). 13C NMR 400 MHz: (DMSO-d6, δ ppm): 53.6, 62.4, 67.0, 99.5, 114.1, 
117.9, 120.4, 124.4, 132.5, 144.5, 153.7, 161.7, 169.6 Mass: [m/e (%)], M. Wt.: 288. 
Elemental analysis, Calculated: C, 62.49; H, 5.59; N, 9.72. Found: C, 62.35; H, 
5.63; N, 9.65. 
N-(2-oxo-2H-chromen-4-yl)-2-(piperazin-1-yl)acetamide  (DPB-3) 
IR (KBr) cm-1: 3496 (-NH), 1275 (C-N, str), 1712 (>C=O), 1652 (-CONH), 2920 
(>CH2 ,str), 1362 (>CH2 ,ban), 3058 (-CH, str), 3060 (Ar, C-H, str), 1550 (Ar, C=C, 
str), 3185 (2nd amine) Mass: [m/e (%)], M. Wt.: 287. Elemental analysis, 
Calculated: C, 62.71; H, 5.96; N, 14.63. Found: C, 62.79; H, 5.99; N, 14.55. 
2-(4-Methylpiperazin-1-yl)-N-(2-oxo-2H-chromen-4-yl)acetamide (DPB-4) 
IR (KBr) cm-1: 3392 (-NH), 1260 (C-N, str), 1722 (>C=O), 1685 (-CONH), 2936 
(>CH2 ,str), 1374 (>CH2 ,ban), 3023 (-CH, str), 3086 (Ar, C-H, str), 1423 (Ar, C=C, 
str), 1368 (-CH3, str) Mass: [m/e (%)], M. Wt.: 301. Elemental analysis, 
Calculated: C, 63.77; H, 6.36; N, 13.94. Found: C, 63.82; H, 6.25; N, 13.87. 
2-(4-Ethylpiperazin-1-yl)-N-(2-oxo-2H-chromen-4-yl)acetamide (DPB-5) 
IR (KBr) cm-1: 3471 (-NH), 1192 (C-N, str), 1730 (>C=O), 1691 (-CONH), 2881 
(>CH2 ,str), 1377 (>CH2 ,ban), 3027 (-CH, str), 3063 (Ar, C-H, str), 1564 (Ar, C=C, 
str), 1368 (-CH3, str.). 1H NMR 400 MHz: (DMSO-d6, δ ppm): 1.18 (t, 3H, -CH3), 
2.51 (q, 2H, -CH2), 2.61 (m, 4H, -CH2), 2.76(m, 4H, -CH2), 3.28 (s, 2H, -CH2), 7.28-
7.62(m, 5H, Ar-H), 10.30 (s, broad, 1H,-NH) 13C NMR 400 MHz: (DMSO-d6, δ 
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ppm): 12.0, 52.2, 53.3, 53.5, 62.0, 99.8, 114.1, 118.2, 119.7, 124.2, 132.3, 144.3, 
153.6, 161.9, 169.5  Mass: [m/e (%)], M. Wt.: 315. Elemental analysis, 
Calculated: C, 64.74; H, 6.71; N, 13.32. Found: C, 64.70; H, 6.63; N, 13.22. 
2-(4-Benzylpiperazin-1-yl)-N-(2-oxo-2H-chromen-4-yl)acetamide (DPB-6) 
IR (KBr) cm-1: 3462 (-NH), 1320 (C-N, str), 1730 (>C=O), 1670 (-CONH), 2858 
(>CH2 ,str), 1389 (>CH2 ,ban), 3042 (-CH, str), 3023 (Ar, C-H, str), 1544 (Ar, C=C, 
str). 1H NMR 400 MHz: (DMSO-d6, δ ppm): 2.59 (m, 4H, -CH2), 2.60 (m, 4H, -
CH2), 3.29 (s, 2H, CH2), 3.9 (s, 2H, -CH2) 7.26-7.67 (m, 10H, Ar-H), 10.40 (s, broad, 
1H,-NH) 13C NMR 400 MHz: (DMSO-d6, δ ppm): 39.3, 39.9, 40.1, 40.4, 53.6, 61.9, 
62.6, 99.3, 114.0, 117.9, 120.1, 124.4, 127.2, 128.2, 129.1, 132.4, 137.4, 144.7, 153.7, 
161.9, 169.8 Mass: [m/e (%)], M. Wt.: 377. Elemental analysis, Calculated: C, 
70.01; H, 6.14; N, 11.13. Found: C, 69.96; H, 6.08; N, 11.02. 
N-(2-oxo-2H-chromen-4-yl)-2-(4-phenylpiperazin-1-yl)acetamide (DPB-7) 
IR (KBr) cm-1: 3420 (-NH), 1310 (C-N, str), 1700 (>C=O), 1655 (-CONH), 2848 
(>CH2 ,str), 1332 (>CH2 ,ban), 3065 (-CH, str), 3050 (Ar, C-H, str), 1532 (Ar, C=C, 
str). Mass: [m/e (%)], M. Wt.: 363. Elemental analysis, Calculated: C, 69.41; H, 
5.82; N, 11.56. Found: C, 69.37; H, 5.78; N, 11.46. 
N-(2-oxo-2H-chromen-4-yl)-2-(pyrrolidin-1-yl)acetamide (DPB-8) 
IR (KBr) cm-1: 3482 (-NH), 1269 (C-N, str), 1728 (>C=O), 1675 (-CONH), 2853 
(>CH2 ,str), 1372 (>CH2 ,ban), 3042 (-CH, str), 3100 (Ar, C-H, str), 1498 (Ar, C=C, 
str). Mass: [m/e (%)], M. Wt.: 272. Elemental analysis, Calculated: C, 66.16; H, 
5.92; N, 10.29. Found: C, 66.25; H, 5.87; N, 10.20. 
2-(Diphenylamino)-N-(2-oxo-2H-chromen-4-yl)acetamide (DPB-9) 
IR (KBr) cm-1: 3462 (-NH), 1325 (C-N, str), 1736 (>C=O), 1685 (-CONH), 2858 
(>CH2 ,str), 1393 (>CH2 ,ban), 3039 (-CH, str), 3028 (Ar, C-H, str), 1530 (Ar, C=C, 
str). Mass: [m/e (%)], M. Wt.: 370. Elemental analysis, Calculated: C, 74.58; H, 
4.90; N, 7.56. Found: C, 74.40; H, 4.98; N, 7.43. 
2-(Diethylamino)-N-(2-oxo-2H-chromen-4-yl)acetamide (DPB-10) 
IR (KBr) cm-1: 3325 (-NH), 1258 (C-N, str), 1732 (>C=O), 1679 (-CONH), 2848 
(>CH2 ,str), 1370 (>CH2 ,ban), 3052 (-CH, str), 3063 (Ar, C-H, str), 1562 (Ar, C=C, 
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str), 1368 (-CH3, str.). Mass: [m/e (%)], M. Wt.: 274. Elemental analysis, 
Calculated: C, 65.68; H, 6.61; N, 10.21. Found: C, 65.60; H, 6.51; N, 10.11. 
2-(2-Methylpiperidin-1-yl)-N-(2-oxo-2H-chromen-4-yl)acetamide (DPB-11) 
IR (KBr) cm-1: 3426 (-NH), 1325 (C-N, str), 1721 (>C=O), 1686 (-CONH), 2956 
(>CH2 ,str), 11421 (>CH2 ,ban), 33065 (-CH, str), 3075 (Ar, C-H, str), 1523 (Ar, C=C, 
str), 1360 (-CH3, str.). Mass: [m/e (%)], M. Wt.: 300. Elemental analysis, 
Calculated: C, 67.98; H, 6.71; N, 9.33 Found: C, 67.88; H, 6.84; N, 9.09. 
2-(2-Chlorophenylamino)-N-(2-oxo-2H-chromen-4-yl)acetamide (DPB-12) 
IR (KBr) cm-1: 3325 (-NH), 1258 (C-N, str), 1732 (>C=O), 1679 (-CONH), 2848 
(>CH2 ,str), 1370 (>CH2 ,ban), 3052 (-CH, str), 3063 (Ar, C-H, str), 1562 (Ar, C=C, 
str), 710 (ortho sub.). Mass: [m/e (%)], M. Wt.: 328. Elemental analysis, 
Calculated: C, 62.11; H, 3.99; N, 8.52 Found: C, 62.16; H, 3.87; N, 8.45. 
2-(3-Chlorophenylamino)-N-(2-oxo-2H-chromen-4-yl)acetamide (DPB-13) 
IR (KBr) cm-1: 3336 (-NH), 1265 (C-N, str), 1722 (>C=O), 1640 (-CONH), 2835 
(>CH2 ,str), 1362 (>Mass: [m/e (%)], M. Wt.: 328. Elemental analysis, Calculated: 
C, 62.11; H, 3.99; N, 8.52 Found: C, 61.18; H, 4.11; N, 8.60. 
2-(o-Tolylamino)-N-(2-oxo-2H-chromen-4-yl)acetamide (DPB-14) 
IR (KBr) cm-1: 3325 (-NH), 1258 (C-N, str), 1732 (>C=O), 1679 (-CONH), 2848 
(>CH2 ,str), 1370 (>CH2 ,ban), 3052 (-CH, str), 3063 (Ar, C-H, str), 1562 (Ar, C=C, 
str), 1368 (-CH3, str.), 715 (ortho sub.). Mass: [m/e (%)], M. Wt.: 308. Elemental 
analysis, Calculated: C, 70.12; H, 5.23; N, 9.09 Found: C, 70.66; H, 5.30; N, 9.15. 
2-(m-Tolylamino)-N-(2-oxo-2H-chromen-4-yl)acetamide (DPB-15) 
IR (KBr) cm-1: 3442 (-NH), 1260 (C-N, str), 1728 (>C=O), 1688 (-CONH), 2898 
(>CH2 ,str), 1389 (>CH2 ,ban), 3027 (-CH, str), 3096 (Ar, C-H, str), 1523 (Ar, C=C, 
str), 1368 (-CH3, str.), 765 (meta sub.). Mass: [m/e (%)], M. Wt.: 308. Elemental 
analysis, Calculated: C, 70.12; H, 5.23; N, 9.09 Found: C, 69.95; H, 5.63; N, 9.15. 
2-(3-Nitrophenylamino)-N-(2-oxo-2H-chromen-4-yl)acetamide (DPB-16) 
IR (KBr) cm-1: 3355 (-NH), 1285 (C-N, str), 1714 (>C=O), 1680 (-CONH), 2869 
(>CH2 ,str), 1450 (>CH2 ,ban), 3010 (-CH, str), 3052 (Ar, C-H, str), 1523 (Ar, C=C, 
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str), 1525 (Nitro gp), 765 (meta sub.). Mass: [m/e (%)], M. Wt.: 339. Elemental 
analysis, Calculated: C, 60.18; H, 3.86; N, 12.38 Found: C, 59.58; H, 3.46; N, 12.09. 
2-(4-Nitrophenylamino)-N-(2-oxo-2H-chromen-4-yl)acetamide (DPB-17) 
IR (KBr) cm-1: 3345 (-NH), 1221 (C-N, str), 1721 (>C=O), 1665 (-CONH), 2885 
(>CH2 ,str), 1469 (>CH2 ,ban), 3075 (-CH, str), 3065 (Ar, C-H, str), 1536 (Ar, C=C, 
str), 1564 (Nitro gp),  863 (pera- sub.). Mass: [m/e (%)], M. Wt.: 339. Elemental 
analysis, Calculated: C, 60.18; H, 3.86; N, 12.38 Found: C, 60.25; H, 3.93; N, 12.45. 
2-(2-Methoxyphenylamino)-N-(2-oxo-2H-chromen-4-yl)acetamide (DPB-18) 
IR (KBr) cm-1: 3330 (-NH), 1261 (C-N, str), 1732 (>C=O), 1655 (-CONH), 2896 
(>CH2 ,str), 1362 (>CH2 ,ban), 3054 (-CH, str), 3063 (Ar, C-H, str), 1562 (Ar, C=C, 
str), 1361 (-CH3, str.), 723 (ortho sub.). Mass: [m/e (%)], M. Wt.: 324. Elemental 
analysis, Calculated: C, 66.66; H, 4.97; N, 8.64 Found: C, 66.50; H, 4.85; N, 8.72. 
2-(3-Methoxyphenylamino)-N-(2-oxo-2H-chromen-4-yl)acetamide (DPB-19) 
IR (KBr) cm-1: 3337 (-NH), 1232 (C-N, str), 1732 (>C=O), 1652 (-CONH), 2920 
(>CH2 ,str), 1372 (>CH2 ,ban), 3023 (-CH, str), 3055 (Ar, C-H, str), 1485 (Ar, C=C, 
str), 1358 (-CH3, str.), 772 (meta sub.). Mass: [m/e (%)], M. Wt.: 324. Elemental 
analysis, Calculated: C, 66.66; H, 4.97; N, 8.64 Found: C, 66.60; H, 4.86; N, 8.55. 
2-(4-Fluorophenylamino)-N-(2-oxo-2H-chromen-4-yl)acetamide (DPB-20) 
IR (KBr) cm-1: 3319 (-NH), 1238 (C-N, str), 1720 (>C=O), 1689 (-CONH), 2847 
(>CH2 ,str), 1483 (>CH2 ,ban), 3075 (-CH, str), 3066 (Ar, C-H, str), 1533 (Ar, C=C, 
str), 875 (pera- sub.).  Mass: [m/e (%)], M. Wt.: 312. Elemental analysis, 
Calculated: C, 65.38; H, 4.20; N, 8.97 Found: C, 65.24; H, 3.26; N, 8.75. 
2-(3-Chloro-4-fluorophenylamino)-N-(2-oxo-2H-chromen-4-yl)acetamide(DPB-21) 
IR (KBr) cm-1: 3469 (-NH), 1268 (C-N, str), 1732 (>C=O), 1678 (-CONH), 2898 
(>CH2 ,str), 1378 (>CH2 ,ban), 3035 (-CH, str), 3082 (Ar, C-H, str), 1524 (Ar, C=C, 
str), 825 (di sub.). Mass: [m/e (%)], M. Wt.: 346. Elemental analysis, Calculated: 
C, 58.89; H, 3.49; N, 8.08 Found: C, 59.96; H, 3.53; N, 8.00. 
2-(3-(Trifluoromethyl)phenylamino)-N-(2-oxo-2H-chromen-4-yl)acetamide 
(DPB22) 
IR (KBr) cm-1: 3442 (-NH), 1260 (C-N, str), 1728 (>C=O), 1688 (-CONH), 2898 
(>CH2 ,str), 1389 (>CH2 ,ban), 3027 (-CH, str), 3096 (Ar, C-H, str), 1523 (Ar, C=C, 
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str), 765 (meta sub.). Mass: [m/e (%)], M. Wt.: 362. Elemental analysis, 
Calculated: C, 59.67; H, 3.62; N, 7.73 Found: C, 59.50; H, 4.69; N, 7.70. 
2-(2,4-Dimethylphenylamino)-N-(2-oxo-2H-chromen-4-yl)acetamide (DPB-23) 
IR (KBr) cm-1: 3452 (-NH), 1268 (C-N, str), 1725 (>C=O), 1689 (-CONH), 2879 
(>CH2 ,str), 1393 (>CH2 ,ban), 3035 (-CH, str), 3096 (Ar, C-H, str), 1532 (Ar, C=C, 
str), 1368 (-CH3, str.), 825 (di sub.). Mass: [m/e (%)], M. Wt.: 322. Elemental 
analysis, Calculated: C, 70.79; H, 5.63; N, 8.69 Found: C, 71.85; H, 5.45; N, 7.72 
2-(Benzylamino)-N-(2-oxo-2H-chromen-4-yl)acetamide (DPB-24) 
IR (KBr) cm-1: IR (KBr) cm-1: 3445 (-NH), 1275 (C-N, str), 1725 (>C=O), 1678 (-
CONH), 2883 (>CH2 ,str), 1356 (>CH2 ,ban), 3058 (-CH, str), 3085 (Ar, C-H, str), 
1532 (Ar, C=C, str), 1368 (-CH3, str.). Mass: [m/e (%)], M. Wt.: 308. Elemental 
analysis, Calculated: C, 70.12; H, 5.23; N, 9.09 Found: C, 70.23; H, 5.18; N, 9.12 
2-(Cyclohexylamino)-N-(2-oxo-2H-chromen-4-yl)acetamide (DPB-25) 
IR (KBr) cm-1: IR (KBr) cm-1: 3355 (-NH), 1285 (C-N, str), 1714 (>C=O), 1680 (-
CONH), 2869 (>CH2 ,str), 1450 (>CH2 ,ban), 3010 (-CH, str), 3052 (Ar, C-H, str), 
1523 (Ar, C=C, str). Mass: [m/e (%)], M. Wt.: 300. Elemental analysis, 
Calculated: C, 67.98; H, 6.71; N, 9.33 Found: C, 67.90; H, 6.65; N, 9.38 
N-(2-oxo-2H-chromen-4-yl)-2-(phenylamino)acetamide (DPB-26) 
IR (KBr) cm-1: IR (KBr) cm-1: 3359 (-NH), 1276 (C-N, str), 1710 (>C=O), 1686 (-
CONH), 2864 (>CH2 ,str), 1455 (>CH2 ,ban), 3011 (-CH, str), 3045 (Ar, C-H, str), 
1529 (Ar, C=C, str). Mass: [m/e (%)], M. Wt.: 294. Elemental analysis, 
Calculated: C, 69.38; H, 4.79; N, 9.52 Found: C, 69.46; H, 4.71; N, 9.48 
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1.11 CONCLUSION 
 
Total 26 derivatives of N-(2-oxo-2H-chromen-4-yl)-2-(substituted amine -1-yl) 
acetamide were synthesized in this chapter. All the synthesized compounds were 
characterized by IR, 1H NMR, 13C, Mass spectroscopy and Elemental analysis. In 
addition the newly synthesized compounds were screened for anti-tubercular activity. 
All the synthesized compounds found less active against tuberculosis strains in vitro.  
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IR spectrum of 2-(4-Ethylpiperazin-1-yl)-N-(2-oxo-2H-chromen-4-yl)acetamide 
(DPB-5) 
 
IR spectrum of 2-(4-Fluorophenylamino)-N-(2-oxo-2H-chromen-4-yl)acetamide 
(DPB-20) 
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2.1 INTRODUCTION 
 
Bridge nitrogen containing fused heterocycles represents important building blocks in 
both natural and synthetic bioactive compounds which have been shown to possess 
diverse therapeutic activities.1 Hence they are interesting target for research as 
therapeutically important heterocyclic entities. Aza-indolizine are of two types, 
imidazo[1,2-a]pyridine and imidazo[1,5-a]pyridine (Figure-1).  
 
 
 
Figure-1 
 
The aza-indolizine containing a phenyl ring fused to a imidazole ring is indicated in 
the structure, hence it is also known as imidazo[1,2-a]pyridine.2 Several procedure for 
their synthesis have been extensively studied. Such studies have been stimulated by 
various promising applications, especially in the case of bridgehead nitrogen 
containing fused heterocyclic entities. 
 
The constitution of imidazo[1,2-a]pyridine was reviewed by W. L. Mosby3 in 1961. 
imidazo[1,2-a]pyridine derivatives not only known for their pharmacological 
applications, they are also used in disperse dyes.4 
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2.2 PHARMACOLOGY 
 
Imidazo[1,2-a]pyridines are potential bioactive agents due to their wide spectrum of 
therapeutic importance. A large number of substituted imidazo[1,2-a]pyridine 
derivatives are prepared and tested for varieties of biological activities such as, 
 
1. Anti-inflammatory, analgesic, antipyretic5,6 
2. Antiviral7,8 
3. Antianxiety9 
4. Antiulcer10,11 
5. Antifungal agents12 
6. Anthelmintic13 
7. Antibacterials14,15 
8. Hypnotic16 
9. Antiherpetie17,18 
10. Gastric antisecretory19,20 
11. Hypnoselective and anxioselective21 
12. β-Amyloid formation inhibitors22 
13. Benzodiazepine receptor agonists23 
14. Nonsedative anxiolytic24 
15. Active nonpeptide bradykinin B2 receptor antagonists24 
16. Cardio tonic agents26 
17. Anticytomegalo-zoster and antivaricellazoster virus27-29 
18. Long-acting local anesthetic30 
19. Calcium channel blockers31 
 
Alexander C. Humphries and et al32 have synthesized 8-fluoro imidazo[1,2-a]pyridine 
derivatives (Figure-2) and evaluated as a bioisosteric replacement for imidazo[1,2-
a]pyridine in an allosteric modulator ligand of the GABAA receptor. Kristjan S. 
Gudmundsson and co-workers33 reported the synthesis and antiviral activity of newer 
erythrofuranosyl imidazo[1,2-a]pyridine C-nucleosides. I. Aramori et al.34 have been 
synthesized imidazo[1,2-a]pyridine derivatives which are highly potent and selective 
non-peptide bradykinin receptor antagonist (Figure-2). 
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Figure-2 
 
Several imidazo[1,2-a]pyridine nucleus already in market which include alpidem35 [a 
ligand of both the central benzodiazepine receptors and the peripheral type 
(Mitochondrial) benzodiazepine receptor] has sedative and anxiolytic properties and 
zolpidem35 [a selective ligand for the central benzodiazepine receptor] is a hypnotic 
drug (Figure-3). Both alpidem and zolpidem have higher affinity for benzodiazepine 
than for benzodiazepine-2 receptors36 and their interaction with various receptors has 
been repoted.37  
 
 
 
Figure-3 
 
James J. Kaminski et al38 have investigated imidazo[1,2-a]pyridine derivative 3-
(cyanomethyl)-2-methyl-8-(phenylmethoxy)imidazo[1,2-a]pyridine (Figure-4) for an 
antiulcer activity. On the basis of the reported metabolism of zolimidine, they 
reported that the 3-cyanomethyl and 8-phenylmethoxy group have been established as 
metabolic sites. 
 
 
 
Figure-4 
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Brian A. Johns et al.39 and Chaouni-Bendallah A. et al.40 synthesized a novel 
imidazo[1,2-a]pyridines (Figure-5) with potent activity against herpes simplex 
viruses. Sophic Ceard et al41 have synthesized some newer imidazo[1,2-a]pyridine 
derivatives (Figure-5) as bioactive agent. Imidazo[1,2-a]pyridine units appear as 
important building blocks in both natural and synthetic bioactive compounds42-44 and 
recognition on DNA binding and to yield different pharmacokinetic profile. 
 
 
 
Figure-5 
 
Mohamed A. Ismail et al45 have synthesized some newer diamine imidazo[1,2-
a]pyridine (Figure-6), 5,6,7,8-tetrahydo imidazo[1,2-a]pyridines and their 
corresponding N-hydroxy and N-methoxy analogues and evaluated against 
Trypanosoma B. Rhodesiense (T. B. Rhodesiense) and Plasmodium Falciparum (P. 
Falciparum). Aromatic diamidines exhibit broad spectrum antimicrobial activity 
including effectiveness against the protozoan disease caused by Trypanosoma SP and 
Plasmodium SP.46 
 
 
 
Figure-6 
 
2.2.1 p38 MAP (Mitogen-activated protein) kinase 
Laufer et. al.47 reported  a series of polysubstituted pyridin-4-yl imidazole inhibitors 
of p38 MAP  kinase which was prepared as small molecular anticytokine agents and 
drug candidates for the treatment of chronic inflammatory diseases. The contribution 
of substituents at the pyridine and imidazole moiety to selective inhibition of p38 
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without concomitant cytochrome P450 interaction was evaluated. Placement of a 1-
phenylethyl (p38: IC50 0.38 µM) or acetyl substituent at the exocyclic nitrogen of 
several 2-aminopyridine imidazoles led to the identification of potent p38 inhibitors 
which exceeded the starting lead ML 3375 (p38: IC50 0.63 µM) in potency (Figure-7). 
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Figure-7: Schematic drawing of important interactions between the 
prototypicalpyridine-4-yl imidazole inhibitor of SB 203580 and the ATP binding 
site of p38 
 
A preliminary modeling study related the enhanced bioactivity of 1-phenylethyl 
substituent to a novel interaction between its 1-phenylethylamino side chain and a 
hydrophobic pocket close to the linker region of p38. The most active p38 inhibitors 
in this series maintained their efficacy in functional PBMC (peripheral blood 
mononuclear cells) and whole blood assays (Figure-8). 
    
 
Figure-8: Banzylsulfulfanylimdazoles and modeling of 7g into the ATP cleft of 
p38 MAP Kinase. The arrows denote the hydrophobic area in close proximity to 
the linker region which stretches both above and below the pyridine ring. 
 
Laufer et al48 then prepared novel 1,2,4,5-tetrasubstituted imidazole derivatives with 
high anti-inflammatory activity. Systematic optimization of the imidazole N-1 
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substituent resulted in a compound that potently inhibited the mitogen activated 
protein kinase p38 (p38 IC50 ) 0.218 µM) as well as the release of the 
proinflammatory cytokines interleukin-1α (L-1α) and tumor necrosis factor R (TNFR) 
from human whole blood after stimulation with LPS. Furthermore, this compound 
exhibited reduced cytochrome P450 interaction in comparison with SB203580. This 
result is particularly important, since cytochrome P450 interaction is observed for 
some p38 inhibitors and in turn can potentially cause drug-drug interaction or lead to 
other hepatic changes such as P450 enzyme induction (Figure-9). 
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Figure-9: Representation of the active site interactions between SB 203580 and 
p38-MAPK 
 
A new therapeutic drug target for the treatment of inflammatory disorders is the 
mitogen-activated protein kinase (MAPK) p38.49-52 P38 is a serine/threonine kinase 
that is part of the stress-activated signal transduction cascade that transducers 
extracellular signals to intracellular response, e.g. cytokine production.53,54 Activated 
p38 phosphorylates other kinases or transcription factors, leading to mRNA 
stabilization or expression of certain target genes.55-57 
Pyridinylimidazoles (i.e. SB203580) are potent and selective inhibitors of p38-
MAPK758,59 by competing with ATP for binding to the ATP pocket.60-62 This small 
hydrophobic pocket near the ATP-binding site is responsible for the selectivity of 
SB203580 for p38 compared to most other kinases.63,64 The pyridin-4-yl moiety is 
essential for the inhibitory potency and generates a pivotal hydrogen bond with the 
amino backbone of Met109 through its pyridinium nitrogen65  (Figure-10). 
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Figure-10: Pyidinylimidazole inhibitors of p-38-MAP kinase. 
 
Table-1: Inhibition of p-38-MAP kinase by acetylaminopyridines. 
N
N
N
F
R1
NHH3C
O
S
CH3
 
Comp.              R1 
IC50 ± (µM) 
P38α 
1 -(CH2)-OH 0.398±0.037 (n=3) 
2 -(CH2)2-O-CH3 0.218±0.010 (n=3) 
3 -(CH2)3-OH 0.813±0.040 (n=3) 
4 -(CH2)3-O-CH3 0.205±0.027 (n=3) 
5 -(CH2)2O-(CH2)2-OH 8.479±0.384 (n=2) 
6 -(CH2)-CH-(CH3)-OH 8.692±0.188 (n=2) 
7 -(CH2)2-NH-COCH 7.29 (n=1) 
8 -(CH2)2-N(CH3)2 2.409±0.145 (n=3) 
9 -(CH2)2OCH2CH=CH2   1.85±0.753 (n=3) 
10 -(CH2)2OCH2C≡CH 0.666±0.148 (n=3) 
11 -(CH2)2-S-CH3 0.431±0.1 (n=3) 
12 -(CH2)-CH(OCH3)2 4.099±1.690 (n=2) 
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13 
     
 
3.732±2.116 (n=2) 
14  
 
2.029±0.686 (n=2) 
16 
 
 
1.343±0.576 (n=2) 
17 
      
 
> 10 
SB 203580  0.462±0.025 (n=6) 
α Results are given as mean of two independent experiments except stated 
otherwise. 
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2.3  SYNTHETIC ASPECT 
 
Classical methods have been reported in the literature for the synthesis of 
imidazo[1,2-a]pyridines. The procedure for synthesizing imidazo[1,2-a]pyridines 
have been described as under. 
 
The synthesis of imidazo[1,2-a]pyridine from 2-aminopyridine with α-
bromoacetophenone was reported by Tschitschibabine.66 
 
2-Acetylimidazo[1,2-a]pyridine67 can be constructed by the cyclocodensation of 2-
aminopyridine with bromo butanedione. 
 
 
 
Reaction of 2-chloropyridine with 1,2,3-triazoles and subsequent elimination of 
nitrogens give the imidazo[1,2-a]pyridine.68 
 
 
 
Condensation of ethyl-6-aminonicotinate with chloroacetaldehyde according to 
Hand’s procedure gave imidazo[1,2-a]pyridine-6-carbaldehyde.69 
 
 
 
Paudler et al.70 have synthesized 5-amino-3-formylimidazo[1,2-a]pyridine from acid 
catalyzed hydrolysis of 1,4-diazacycl[3,2,2]azine. 
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Imidazo[1,2-a]pyridine71 nucleus can be also synthesized by the reaction of α-
ketohydrazidoyl halide with heterocyclic amines. 
 
 
 
Tsai et al.72 have been prepared 3-amino imidazo[1,2-a]pyridine derivatives by a 
three component condensation reaction between 2-aminopyridine, aldehyde and 
isonitrile in the presence of scandiumtriflate as a catalyst. 
 
 
 
Groziak et al.73 have synthesized substituted imidazo[1,2-a]pyridine derivatives by 
the condensation of 2-aminopyridine with glyoxal trimer dehydrate in aqueous 
NaHSO3. 
 
 
 
Synthesis of Cu(OTf)2-catalyzed imidazo[1,2-a]pyridines from α-diazoketones and 2-
aminopyridines by J. S. Yadav.74 
 
 
 
Jumat Salimon et al.75 synthesized imidazo[1,2-a]pyridine-3(2H)-one & 3-substituted-
4-yl imidazo[1,2-a] pyridine from 2-aminopyridine. 
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N NH2
N N
(a)
N N
N N
O
(c)
(b)
(i) (ii) (iii)
(i) 4-phenyl phenacyl bromide
(ii) phenacyl chloride
(iii) chloro aceticacid
 
 
Shankarappa A Biradar76 have synthesized 6-bromo-2-(3,4-dichlorophenyl) 
imidazo[1,2-a]pyridine using microwave irradiation from 5-bromo-2-aminopyridine 
and 2-bromo-1-(3,4-dichlorophenyl)ethanone. 
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2.4  AIM OF CURRENT WORK 
 
The literature survey revealed that some extensive work has been done on imidazo 
[1,2-a]pyridine compounds. A series of substituted imidazo[1,2-a]pyridine inhibitors 
of p38 MAP (Mitrogen-activated protein) kinase was prepared as small molecular 
library for the treatment of inflammatory diseases. From the literature of medicinal 
chemistry the most useful moiety found was substituted imidazo[1,2-a]pyridine 
derivatives, because of the less toxicological properties and good to moderate 
activities. 
 
Based on these observations, a new series of 15 compounds have been synthesized by 
taking 4-(1-bromo-2-(4-fluorophenyl)-2-oxoethyl)pyridin-2-ylcarbamate coupled with 
various 2-aminopyridines and thiourea, to give 4-(2-(4-fluorophenyl)H-imidazo[1,2-
a]pyridin-3-yl)  pyridin-2-amine derivatives. The synthesized compounds were 
screened for anti-inflammatory activity and results are awaited. 
2.5  REACTION SCHEME 
 
 
a) (Boc)2O, t-BuOH, 28 °C, 24 h 
b) N-butyllithium, dry THF, (4-fluorophenyl)(morpholino)methanone, -76 °C 
c) N-bromo succinamide, 27 °C, 1.5 h. 
d) (i)  2-Amino pyridine derivatives 
(ii) Thiourea derivatives, DMF, 75 °C 
e) Acidic silica, MW 
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2.6  PLAUSIBLE REACTION MECHANISM 
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2.7 EXPERIMENTAL 
 Preparation of Tert-butyl 4-methylpyridin-2-ylcarbamate 
A mixture of 4-methylpyridin-2-amine (0.1 mole ) was dissolved in t-butyl alcohol in 
to 100ml round bottom flask. Boc anhydride (0.15 mole) was added to the above 
flask. The reaction mixture was stirred at room temperature for 24 h. The progress and 
the completion of the reaction were checked by silica gel-G F254 thin layer 
chromatography using hexane: ethyl acetate (9:1) as a mobile phase. After the 
reaction was completed, the reaction was pored in to the ice and extracted with ethyl 
acetate. The organic layer was separated out and dried with sodium sulphate. The 
organic layer was evaporated under vaccum to give yellow oily compound. The 
compound was purified by column chromatography by silica gel 230-400 mash. Yield 
: 73% 
 Preparation of 1-(4-Fluorophenyl)-2-(2-(N-Boc amino)pyridin-4-yl) 
ethanone 
A mixture of tert-butyl 4-methylpyridin-2-ylcarbamate (0.1 mole ) was dissolved in 
dry THF in a 250ml round bottom flask. N-butyl lithium (0.3 mole) was drop wise 
added to the above flask at -78 °C. Resulting reaction mixture was stirred at room 
temperature for 35 min. Now the (4-fluorophenyl)(morpholino)methanone (0.1 mole) 
was added drop wise into the reaction mixture at -78 °C. The reaction mixture was 
stirred for 2 h at room temperature. After the reaction was completed, the reaction was 
poured in to the ice and extracted with ethyl acetate. The organic layer was separated 
out and dried with sodium sulphate. The organic layer was evaporated under vaccum 
to give yellow oily compound. The compound was purified by column 
chromatography by silica gel 230-400 mash. TLC (EtoAC: Hexane, 2:8). Yield : 61%. 
Note: The entire reaction was carried out under nitrogen atmosphere. 
          
 Preparation of Tert-butyl 4-(1-bromo-2-(4-fluorophenyl)-2-oxoethyl) 
pyridin-2-ylcarbamate 
1-(4-Fluorophenyl)-2-(2-(N-Boc amino)pyridin-4-yl)ethanone (0.1 mole) was 
dissolved in dioxane in a 100ml round bottom falsk. N-bromo succinamide (0.1 mole) 
was added to  the above flask. The reaction mixture was stirred at room temperature 
for 1.5 h. The progress and the completion of the reaction were checked by TLC using 
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hexane: ethyl acetate (8:2) as a mobile phase. After the reaction to be completed, the 
reaction was poured in to the ice to give yellow solid compound. Yield : 85%. 
 Preparation of Tert-butyl 4-(2-(4-fluorophenyl)H-imidazo[1,2-a]pyridin-
3-yl)pyridin-2-ylcarbamate derivatives  
Tert-butyl 4-(1-bromo-2-(4-fluorophenyl)-2-oxoethyl)pyridin-2-ylcarbamate (0.1 
mole) was dissolved in DMF in a 100ml round bottom falsk. Substituted  2-amino 
pyridine (0.1 mole) / substituted thiourea (0.1 mole)  was also added in to flask. The 
resulting mixture was heated at    75 °C for 1 h to give solid compound. The reaction 
mixture was cooled at room temperature, filtered  and washed with ether. TLC 
(EtoAC: Hexane, 4:6), Yield : 82%. 
 Preparation of 4-(2-(4-Fluorophenyl)H-imidazo[1,2-a]pyridin-3-yl)  
pyridin-2-amine derivatives 
The typical procedure, N-BOC- 4-(3-(3-fluorophenyl)H-imidazo[1,2-a]pyridin-2-
yl)pyridin-2-ylcarbamate derivatives (0.1 mole) were treated with acidic silica 
(0.2mole) under microwave irradiation at 250 W, 80°C in methanol. All the BOC-
amine was deprotected in 2.5-5.0 min. The reaction was readily monitored by TLC. 
After completion of reaction, the silica was removed by simple filtration and the 
solvent was evaporated to dryness to give desired product. The pure 4-(3-(3-
fluorophenyl)H-imidazo[1,2-a]pyridin-2-yl)pyridin-2-amine derivatives were isolated 
between 80-90% yield in one step. No additional purification steps were required. The 
final compounds were furthermore confirmed by 1H NMR spectra, here N-Boc 
protected amide proton was observed at 8.0-9.0 δ ppm where N-Boc deprotected free 
amine proton was demonstrated at 5.5-6.5 δ ppm.  
. 
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2.8 PHYSICAL DATA  
TABLE: 2  PHYSICAL DATA OF 4-(3-(3-FLUOROPHENYL)H-
IMIDAZO[1,2-a]PYRIDIN-2-YL)PYRIDIN-2-AMINE AND 
THIOUREA DERIVATIVES 
Sr. No 
 
Substituted M.F. 
M. P 
(oC) Rf value 
% 
Yield 
DPB-27 C18H13FN4 184-186 0.36    87 
DPB-28 C19H15FN4 156-158 0.39 
 
   85 
DPB-29 C19H15FN4 196-198 0.51    85 
DPB-30 C19H15FN4 210-212 0.42    87 
DPB-31 C19H15FN4 246-248 0.48    76 
DPB-32 C18H12BrFN4 188-190 0.37    88 
DPB-33 
 
C18H12ClFN4 176-178 0.46    88 
DPB-34 
 
C18H12BrFN4 212-214 0.33    85 
DPB-35 C18H11Cl2FN4 276-278 0.53    87 
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DPB-36 C18H12FN5O2 222-224 0.38    72 
DPB-37 C14H11FN4S 189-191 0.41    87 
DPB-38 C15H13FN4S 256-258 0.50    85 
DPB-39 
 
C26H19FN4S 156-158 0.48    84 
DPB-40 C16H13FN4OS 179-181 0.36     87 
DPB-41 C14H12FN5S 245-247 0.44    74 
 
Rf value was calculated using solvent system, EtoAC: Hexane, 5:5. 
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2.9 SPECTRAL STUDY 
 IR spectra 
Infra Red spectra were taken on Shimadzu FT-IR-8400 spectrometer using KBr 
Pellet method. The characteristic amine in imidazol[1,2-a] pyridine moiety is 
observed at 3500-3300 cm-1, while aromatic group are observed in the range 3100-
3000 cm-1. C-X (X=Cl,Br,I,F) observed between 1000-500 cm-1. methyl (-CH3) 
observed at 1350 cm-1.The characteristic C=N in imidazol[1,2-a] pyridine oberseved 
at 1612-1590 cm-1. DPB- 28 and DPB-40 of IR spectra are given on page no: - 73. 
 1H NMR spectra 
1H NMR spectra were recorded on a Bruker AC 400 MHz NMR spectrometer using 
TMS (Tetramethyl Silane) as an internal standard and DMSO-d6 & CDCl3 as a 
solvent. In the NMR spectra of 4-(3-(3-fluorophenyl)H-imidazo[1,2-a]pyridin-2-
yl)pyridin-2-amine derivatives proton values of amine (-NH2), methyl (-CH3) and 
aromatic protons (Ar-H) etc. were observed as under. 
The values for –NH2 protons were observed at 4.0-5.0 δ ppm. Aromatic protons 
shows the multiplet between δ 6.05-8.50 δ ppm. The signal due to -CH3 proton was 
observed at  1.5-2.5 δ ppm value. Intermediate, DPB-27, DPB-28, DPB-33 and DPB-
37 of 1H NMR spectra are given on page no: - 65 to 72. 
N
H2N N
N
F
1
2
3
4 5
6
7
8
9
10
11
12
 
1. The aromatic pyridine ring proton no. 1 gave a doublet at 8.19 δ ppm. It shows 
in spectra due to the coupling with proton no.2 and J values is 8.0Hz from the 
J value, suggesting it is ortho coupled. 
2. The aromatic ring proton no. 4 gave a doublet at 8.17 δ ppm it shows in 
spectrum due to the effect of nitrogen atom  
3. The aromatic ring proton no. 3 gave a characteristic singlet at 7.28 δ ppm. 
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4. The aromatic ring of the phenyl ring proton no. 7, 8 and 11 are on same 
atmosphere so these three protons gave a multiplet at 7.63 δ ppm-7.97 δ ppm it 
shows in spectra. 
5. The aromatic ring of the phenyl ring proton no. 9 and 10 are on same 
atmosphere so these three protons gave a multiplet at 7.02 δ ppm-7.06 δ ppm it 
shows in spectra. 
6. The aromatic pyridine ring proton no. 2 gave a doublet at 6.63 δ ppm it shows 
in spectra due to the coupling with proton no.1 and J values is 8.0Hz from the 
J value, suggesting it is ortho coupled. 
7. The aromatic ring of the phenyl ring proton no. 5 and 6 are on same 
atmosphere so these two protons gave a multiplet at 6.78 δ ppm-6.89 δ ppm it 
shows in spectra. 
8. The proton no. 12 of the –NH2 group gave a characteristic broad singlet at 
6.12 δ ppm. 
 
Thus, by observing and assigning the peaks in the NMR spectrum and by the 
calculation of the J values for each of the above proton, the proposed structure for 
compound DPB-27 was confirmed.  
 13C NMR spectra 
13C NMR spectra were recorded on a Bruker AC 400 MHz NMR spectrometer using 
DMSO-d6 & CDCl3 as a solvent. In the 13C NMR spectra of  substituted 4-(3-(3-
Fluorophenyl)H-imidazo[1,2-a]pyridin-2-yl)pyridin-2-amine various carbon values of 
methylene (-CH2), keto (>C=O), methyl (-CH3) and aromatic carbon (Ar-H) etc. were 
observed as under. 
The values for methylene (-CH2) carbon is observed between 40-60 δ ppm. The 
>C=O carbon observed at 160-185 δ ppm. Aromatic carban shows between  110-145 
δ ppm. Intermediate, DPB-27, DPB-28, DPB-33 and DPB-37 of 13C NMR spectra are 
given on page no: - 65 to 72. 
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1. The carbon no. 2, 8, 11, 13, 15 and 18 of aromatic, appear at 109.67 δ ppm-
117.09 δ ppm. 
2. The carbon no. 3, 4, 5, 7, 12, 14 and 17 of aromatic, appear at 123.19 δ ppm-
129.76 δ ppm. 
3. The carbon no. 6 of imidazole ring, appear at 142.50 δ ppm due to the effect of 
nitrogen atom. 
4. The carbon no. 9 and 16 of imidazole or pyridine ring, appear at 144.88 δ ppm 
due to the effect of nitrogen atom. 
5. The carbon no. 10 of pyridine ring, appear at 142.50 δ ppm due to the effect of 
amino group. 
6. The carbon no. 1 of aromatic ring, appear at 158.30 δ ppm due to the effect of 
fluorine group. 
 
 Mass spectra 
The mass spectrum of compounds were recorded by Shimadzu GC-MS-QP-2010 
spectrometer (EI method). The mass spectrum of compounds was obtained by positive 
chemical ionization mass spectrometry. The molecular ion peak and the base peak in 
all compounds were clearly obtained in mass spectral study. The molecular ion peak 
(M+) values are in good agreement with molecular formula of all the compounds 
synthesized. DPB- 27, DPB-29 and DPB-40 of Mass spectra are given on page no.- 
64 and 65. 
 Elemental analysis 
Elemental analysis of the compounds was carried out on Elemental Vario EL III 
Carlo Erba 1108 model at Saurashtra University, Rajkot  and the results are in 
agreement with the structures assigned. 
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2.10 SPECTRAL CHARACTERIZATION 
4-(3-(3-Fluorophenyl)H-imidazo[1,2-a]pyridin-2-yl)pyridin-2-amine (DPB-27) 
IR (KBr) cm-1: 3355 (-NH, str), 1285 (C-N, str), 1580 (-NH,ban) 1028 (C-F), 3052 
(Ar, C-H, str), 1523 (Ar, C=C, str). 1H NMR 400 MHz: (DMSO-d6, δ ppm): 6.12 (s, 
2H, -NH2), 6.63-7.67 (m, 9H, Ar-H), 8.05 (d,1H, Ar-H), 8.19 (d,1H, Ar-H). 13C NMR 
400 MHz: (DMSO-d6, δ ppm): 39.3, 39.9, 40.1, 40.4, 109.4, 112.6, 113.0, 114.7, 
115.6, 117.0, 123.1, 123.3, 129.4, 129.6, 129.7, 142.5, 144.0, 145.0, 158.3 Mass: 
[m/z (%)], M. Wt.: 304. Elemental analysis, Calculated: C, 71.04; H, 4.31; N, 
18.41 Found: C, 71.12; H, 4.29; N, 18.39. 
4-(2-(3-Fluorophenyl)-8-methylH-imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine 
(DPB-28) 
IR (KBr) cm-1: 3331 (-NH. str), 1290 (C-N, str), 1052 (C-F), 3021 (Ar, C-H, str), 
1510 (Ar, C=C, str), 2845 (-CH3, str), 1348 (-CH3, ban).  1H NMR 400 MHz: 
(DMSO-d6, δ ppm): 1.72 (s, 3H, -CH3), 4.61 (s, 2H, -NH2), 6.7-7.6 (m, 8H, Ar-H), 
8.01 (d, 1H, Ar-H, J=6.4Hz), 8.27 (d, 1H, Ar-H, J=3.2Hz).  Mass: [m/z (%)], M. 
Wt.: 318. Elemental analysis, Calculated: C, 71.68; H, 4.75; N, 17.60 Found: C, 
70.75; H, 4.69; N, 17.55. 
4-(2-(3-Fluorophenyl)-7-methylH-imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine 
(DPB-29) 
IR (KBr) cm-1: 3330 (-NH. str), 1296 (C-N, str), 1082 (C-F), 3070 (Ar, C-H, str), 
1552 (Ar, C=C, str), 2860 (-CH3, str), 1378 (-CH3, ban). Mass: [m/z (%)], M. Wt.: 
318. Elemental analysis, Calculated: C, 71.68; H, 4.75; N, 17.60 Found: C, 70.75; 
H, 4.70; N, 17.45. 
4-(2-(3-Fluorophenyl)-6-methylH-imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine 
(DPB-30) 
IR (KBr) cm-1: 3312 (-NH. str), 1254 (C-N, str), 1042 (C-F), 3052 (Ar, C-H, str), 
1523 (Ar, C=C, str), 2872 (-CH3, str), 1344 (-CH3, ban). 1.65 (s, 3H, -CH3), 4.53 (s, 
2H, -NH2), 6.65 (s, 1H, Ar-H) 6.79-7.62 (m, 9H, Ar-H). Mass: [m/z (%)], M. Wt.: 
318. Elemental analysis, Calculated: C, 71.68; H, 4.75; N, 17.60 Found: C, 71.50; 
H, 4.66; N, 17.52. 
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4-(2-(3-Fluorophenyl)-5-methylH-imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine 
(DPB-31) 
IR (KBr) cm-1: 3386 (-NH. str), 1296 (C-N, str), 1128 (C-F), 3042 (Ar, C-H, str), 
1563 (Ar, C=C, str), 2828 (-CH3, str), 1372 (-CH3, ban).  Mass: [m/z (%)], M. Wt.: 
318. Elemental analysis, Calculated: C, 71.68; H, 4.75; N, 17.60 Found: C, 71.65; 
H, 4.66; N, 17.52. 
4-(7-Bromo-2-(3-fluorophenyl)H-imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine 
(DPB-32) 
IR (KBr) cm-1: 3392 (-NH. str), 1268 (C-N, str), 1025 (C-F), 3056 (Ar, C-H, str), 
1572 (Ar, C=C, str), 534 (C-Br).  Mass: [m/z (%)], M. Wt.: 382. Elemental 
analysis, Calculated: C, 56.42; H, 3.16; N, 14.62 Found: C, 56.50; H, 3.25; N, 14.64. 
4-(7-Chloro-2-(3-fluorophenyl)H-imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine 
(DPB-33) 
IR (KBr) cm-1: 3362 (-NH. str), 1242 (C-N, str), 1058 (C-F), 3072 (Ar, C-H, str), 
1549 (Ar, C=C, str), 725 (C-Cl).  1H NMR 400 MHz: (DMSO-d6, δ ppm): 4.51 (s, 
2H, -NH2), 6.58 (s, 1H, Ar-H), 6.63-7.71 (m, 9H, Ar-H), Mass: [m/z (%)], M. Wt.: 
338. Elemental analysis, Calculated: C, 63.82; H, 3.57; N, 16.54 Found: C, 63.55; 
H, 3.51; N, 16.48. 
4-(2-(3-Fluorophenyl)-7-iodoH-imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine (DPB-
34) 
IR (KBr) cm-1: 3382 (-NH. str), 1241 (C-N, str), 1032 (C-F), 3079 (Ar, C-H, str), 
1585 (Ar, C=C, str), 492 (C-I). Mass: [m/z (%)], M. Wt.: 430. Elemental analysis, 
Calculated: C, 50.25; H, 2.81;N, 13.02 Found: C, 50.05; H, 2.62;N, 13.35. 
4-(6,8-Dichloro-2-(3-fluorophenyl)H-imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine 
(DPB-35) 
IR (KBr) cm-1: 3346 (-NH. str), 1275 (C-N, str), 1015 (C-F), 3053 (Ar, C-H, str), 
1575 (Ar, C=C, str), 742 (C-Cl).  Mass: [m/z (%)], M. Wt.: 372. Elemental 
analysis, Calculated: C, 57.93; H, 2.97;N, 15.01 Found: C, 58.90; H, 2.87; N, 15.11. 
4-(2-(3-Fluorophenyl)-6-nitroH-imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine (DPB-
36) 
IR (KBr) cm-1: 3382 (-NH. str), 1262 (C-N, str), 1046 (C-F), 3041 (Ar, C-H, str), 
1568 (Ar, C=C, str), 1545 (-NO2). Mass: [m/z (%)], M. Wt.: 349. Elemental 
analysis, Calculated: C, 61.89; H, 3.46; N, 20.05 Found: C, 61.81; H, 3.52; N, 20.11. 
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4-(2-Amino-4-(3-fluorophenyl)thiazol-5-yl)pyridin-2-amine (DPB-37) 
IR (KBr) cm-1: 3356 (-NH. str), 1243 (C-N, str), 1043 (C-F), 3092 (Ar, C-H, str), 
1575 (Ar, C=C, str). 1H NMR 400 MHz: (DMSO-d6, δ ppm): 5.9 (s, 2H, -NH2), 7.8 
(s, 2H, -NH2), 6.18 (d, 1H, Ar-H, J=4.8Hz), 6.2 (s, 1H, Ar-H), 7.1 (t, 2H, Ar-H), 7.4 
(t, 2H, Ar-H), 7.3 (d, 1H, Ar-H, J=5.2Hz).  Mass: [m/z (%)], M. Wt.: 286. 
Elemental analysis, Calculated: C, 58.73; H, 3.87; N, 19.57; S, 11.20 Found: C, 
58.63; H, 3.81; N, 19.60; S, 11.10. 
4-(4-(3-Fluorophenyl)-2-(methylamino)thiazol-5-yl)pyridin-2-amine (DPB-38) 
IR (KBr) cm-1: 3330 (-NH. str), 1295 (C-N, str), 1082 (C-F), 3070 (Ar, C-H, str), 
1552 (Ar, C=C, str), 2868 (-CH3, str), 1356 (-CH3, ban). Mass: [m/z (%)], M. Wt.: 
300. Elemental analysis, Calculated: C, 59.98; H, 4.36; N, 18.65; S, 10.68 Found: 
C, 59.88; H, 4.26; N, 18.73; S, 10.75. 
4-(2-(Diphenylamino)-4-(3-fluorophenyl)thiazol-5-yl)pyridin-2-amine (DPB-39) 
IR (KBr) cm-1: 3346 (-NH. str), 1272 (C-N, str), 1016 (C-F), 3076 (Ar, C-H, str), 
1582 (Ar, C=C, str). Mass: [m/z (%)], M. Wt.: 438. Elemental analysis, 
Calculated: C, 71.21; H, 4.37; N, 12.78; S, 7.31Found: C, 71.18; H, 4.29; N, 12.89; 
S, 7.45. 
N-(5-(2-aminopyridin-4-yl)-4-(3-fluorophenyl)thiazol-2-yl)acetamide (DPB-40) 
IR (KBr) cm-1: 3302 (-NH), 1228 (C-N, str), 1687 (-CONH), 2866 (-CH3, str), 1361 
(-CH3, ban). Mass: [m/z (%)], M. Wt.: 328. Elemental analysis, Calculated: C, 
58.52; H, 3.99; N, 17.06; O, 4.87; S, 9.77 Found: C, 58.48; H, 4.21; N, 17.12; O, 
4.90; S, 9.86. 
4-(2-Hydrazine-4-(3-fluorophenyl)thiazol-5-yl)pyridin-2-amine (DPB-41) 
IR (KBr) cm-1: 3375 (-NH. str), 1265 (C-N, str), 1056 (C-F), 3059 (Ar, C-H, str), 
1547 (Ar, C=C, str). Mass: [m/z (%)], M. Wt.: 301. Elemental analysis, 
Calculated: C, 55.80; H, 4.01; N, 23.24; S, 10.64 Found: C, 55.75; H, 4.11; N, 23.32; 
S, 10.54. 
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2.11 CONCLUSION 
Total 15 derivatives of N-4-(3-(3-fluorophenyl)H-imidazo[1,2-a]pyridin-2-yl)pyridin-
2-amine have been synthesized using 2-amino-4-methyl-pyridine. All the compounds 
were characterized by IR, 1H NMR, 13C, Mass spectral data and elemental analysis. 
The main significance of the present process is the easy work up method, excellent 
yield and high chemical purity of the desired compounds for biological interest. 
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3.1     INTRODUCTION 
 
Oxadiazoles belong to an important group of heterocyclic compounds having –N=C-O- 
linkage. 1,3,4-oxadiazole(1) is a thermally stable aromatic heterocycle and exist in two 
partially reduced forms; 2,3-dihydro-1,3,4-oxadiazole(1,3,4-oxadiazoline)(2) and 2,5-
dihydro-1,3,4-oxadiazole(1,3,4-oxadiazoline)(3) depending on the position of the double 
bond. The completely reduced form of the 1,3,4-oxadiazole is known as 2,3,4,5-
tetrahydro-1,3,4-oxadiazole (1,3,4-oxadiazolidine)(4)1 
 
 
1,3,4-Oxadiazole is a heterocyclic molecule with oxygen atom at 1 and two nitrogen 
atoms at 3 and 4 position. They have been known for about 80 years, it is only in the last 
decade that investigations in this field have been intensified. This is because of large 
number of applications of 1,3,4-oxadiazoles in the most diverse areas viz. drug synthesis, 
dye stuff industry, heat resistant materials, heat resistant polymers and scintillators. Re-
views of the relevant literature prior to 1965 are available. 
 
 Bactericidal and/or fungicidal activity was reported for oxadiazole (5a), aminooxadia-
zole (5b)2 and oxadiazolinethiones (6a).3 The tin derivatives (6b) is an effective fungicide 
and antimicrobial activity is shown by thiones (6c).4 Antiinflammatory, sedative and 
analgesic properties were reported for aryloxadiazoles (5c).5 Amino-oxadiazoles (5d) 
show analgesic activity and amino-oxadiazoles (5e) exhibit both anti-inflammatory and 
antiproteolytic properties6. Anticonvulsant and nervous system depressant activity was 
reported for amino-oxadiazoles (5f), where R is quinazolin-3-yl group.7 Aminooxadia-
zole (5g) show local anaesthetic activity.8 The oxadiazolinone (6d) is an orally active an-
tiallergic agent, for example in the treatment of asthma and allergy disease and is claimed 
to be more potent than sodium cromoglycate.9 Examples of the many oxadiazolones for 
the many herbicidal activity (week killers) are (6e,6f) and “oxadiazon”(6g), which is the 
subject of many regular reports in the literature. Insecticidal activity is shown by oxadia-
zolones (6h, 6i the later is an aphicide), and oxadiazole (5h) 
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 R1 
or 
R2  R1 R2 X 
5a Ar CH2CONHCONHR 6a heteroarylOCH2 H S 
5b AR OCH2 NHCOR 6b 
1-
methylcyclopropyl Sn(Ph)3 O 
5c trimethoxy 3,4-dimethoxyphenyl 6c 
5-Cl-2-
phenylindol-3-
ylNH 
H S 
5d 2-pyridyl NR2HCl 6d 
3-Cl-
benzo[b]thiophen-
2-yl 
H O 
5e 4-biphenylylmethyl 
NHAr 
 6e 
4-
cyclohexylphenoxy H O 
5f Ar NHCH2CONHR 6f 
2,4-diCl-
phenoxymethyl Bn O 
5g Ar NHCO(CH2)nNRR'HCl(n=2or3) 6g t-Bu 
2,4-diCl--5-
isopropoxyphenyl O 
   6h OCH3 o-methoxyphenyl O 
    6i CH3NH 
2,3-diH-2,2,4-
triMebenzofuran-
7-yl 
 
O 
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3.2      PHARMACOLOGY 
 
1,3,4-Oxadiazole derivatives have been tested for various pharmacological ac-
tivities, which have been summarized as under. 
1. Antibacterial10 
2. Antiinflammatory11 
3. Analgesic12 
4. Antiviral and anticancer13 
5. Antihypertensive14 
6. Anticonvulsant15 
7. Antiproliferative16 
8. Antifungal17 
9. Cardiovascular18 
10. Herbicidal19 
11. Hypoglycemic20 
12. Hypnotic and Sedative21 
13. MAO inhibitor22 
14. Insecticidal23 
 
1,3,4-Oxadiazole is a versatile scaffold and is being consistently used as a building block 
in organic chemistry as well as in heterocyclic chemistry for the synthesis of different 
heterocycles. The synthetic versatility of 1,3,4-oxadiazole has led to the extensive use of 
this compound in organic synthesis.  
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Some oxadiazole drugs & derivatives under Preclinical/Phase clinical trials. 
 
Sr. No 
 
Chemical structure 
 
 
Activity 
 
 
Phase 
 
 
Originator 
 
1 
Antitussive, 
Bronchodilator 
 
Phase-I 
 
Sanofi-
Synthlabo 
 
2 
Antirhinoviral, 
Antiviral 
 
Phase-III 
 
Viro 
pharma 
 
3 
Antihypertensive, 
Antianginal, 
Antiglaucoma 
agent, 
Beta-adrenoceptor 
antagonist 
 
Phase-II 
 
Center for 
Chemistry 
of Drugs 
 
4 
Antidepressants, 
Anxiolytic, 5-
HT1D Antagonist 
 
Biological 
testing 
 
Smithkline 
Beecham 
 
5 
Antidepressants, 
Anxiolytic, 
5-HT1D Inverse 
agonist 
 
Preclinical 
 
Smithkline 
Beecham 
 
6 
 
Cognition en-
hancing drug, 
GABA(A) recep-
tor modulator, 
GABA(A) B2 site 
inverse 
agonist 
 
Preclinical 
 
Dainoppon 
pharma 
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Some oxadiazole drugs & derivatives under Preclinical/Phase clinical trials. 
 
Sr. No 
 
Chemical structure 
 
 
Activity 
 
 
Phase 
 
 
Originator 
 
1 Analgesic Preclinical 
Universidade 
federal per-
nambuco 
2 
Antiobesity drug, 
Antidiabetic drug, 
Beta3 adrenoce tor 
agonist 
Preclinical Merck 
3 
OH
NHN
S
O
O
N O
N
OCF3
Antiobesity drug, 
Antidiabetic drug, 
Beta3 adrenoceptor 
agonist 
Preclinical Merck 
4 O
H3CO
O N
N
CH3
CN
Bronchodilator, 
Phosphodiesterase 
Inhibitor 
Preclinical 
Smithkline 
Beecham 
 
5 Antitrypanosomal Preclinical 
Universidad 
de larepubli-
ca 
6 
Antiepileptic 
drug,Neuronal In-
jury Inhibitor, 
AMPA antagon-
ist,Sodium channel 
blocker 
Preclinical Boehringer Ingelaeim 
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3.3  SYNTHETIC ASPECT 
 
There were several routes for the synthesis of 1,3,4-oxadiazoles reported in the literature 
among which the most important aspects of synthesis were discussed as under. 
 
2,5-Disubstituted 1,3,4-oxadiazole can be accomplished by cyclodehydration of 1,2-
diacylhydrazine either by using chlorosulphonic acid24 or phenyl dichorophosphite in di-
methylformamide. A nonaqueous, nonacedic, route involves treatment of hydrazine with 
hexamethyl disilazane (HMDS) and tetrabutylammoniumfluoride, the last step presuma-
bly being fluoride catalyzed cyclization of intermediate bis silyl ether25-26 (Scheme-1) 
 
 
In a related reaction, 1,1,2-triacetylhydrazine with trimethylsilylchloride/triethylamine 
gave oxadiazolinyl silylether.27 Cyclodehydration (PCl5/POCl3) of hydrazinyl diester 
gave the diphenyloxyoxadiazole.28 (Scheme-2) 
 
HN N
COCH3
O
R1 R2
O
N
O
N
R2
OSi(CH3)3
R1
O
CH3
HN NH
O
PhO OPh
O
NN
OPhO OPh
(CH3)3SiCl/(Et)3N
1,1,2-triacylhydrazine
R1, R2 = alkyl
Hydrazine diester 2,5-diphenoxy-1,3,4-oxadiazol
POCl3/PCl5
Scheme-2  
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The malonate derivative (1) reacted with acylhydrazine (2) to give a mixture of diacylhy-
drazine monoamine (3) and oxadiazole (4). The later was also formed from (3) by heat-
ing.29 (Scheme-3) 
 
 
Oxidation of acylhydrazones derived (5) from aldehydes has been developed into a useful 
route to disubstituted oxadiazoles (6). The use of potassium permanganate with acetone 
as solvent was claimed to give better yields than the use of other oxidizing agents 
(e.g.halogens).30 An improved synthesis of bis-oxadiazolylbenzenes (8) involved oxida-
tion of bishydrazones (7) with lead tetraacetate.31 Acylhydrazones (9) were oxidized by 
iodosobenzene diacetate to oxadiazolinones (10), with acetates (11) also being formed in 
some cases. A similar oxidation of ethyl esters (9, X=OEt) gave oxadiazolyl ethers (11, 
X=OEt).32 Oxidative cyclization(FeCl3/AcOH) of semicarbazone (12) yielded amino-
oxadiazoles (13).33 (Scheme-4) 
 
Important routes to monosubstituted oxadiazoles (14), aminooxadiazoles (15), oxadiazo-
linones (15a) and oxadiazolinethiones (16) involve reaction of hydrazides 
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(R1CONHNH2) with triethyl orthoformate, cyanogen bromide, phosgene, or carbon dis-
ulphide (or CSCl2) respectively. (Scheme-5) 
 
Reaction of hydrazide (17) with triethylorthoformate, or with CS2/KOH, allowed the syn-
thesis of oxadiazolyl methyl ketones (18) and (19), respectively, after hydrolysis of the 
acetal group.34 (Scheme-6) 
 
O O
CH3
N
H
O
NH2
NN
O
N
O
NH
S
O
CH3
O
CH3
C(OC2H5)3
CS 2/KOH
17
18
19
Scheme-6  
 
An alternative to cyanogenbromide is phenyl cyanate (PhOCN), which reacted with hy-
drazines (R1CONHNH2) to give aminooxadiazoles (R1= 4,6- dimethyl-2-pyrimidyl).35 
From oxadiazol-2-carbohydrazides (20) bioxadiazolyls ( 21) and (22) were prepared us-
ing cyanogen bromide36 or thiophosgene37 respectively. (Scheme-7) 
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R1
O
N
H
NH2
NN
OR1
NH2
OCN
N N
O
R1
O
NH
NH2
N
O
N
O
NN
R1
NH2
N
O
N
O
NN
R1
NH2
R1=4,6-dimethyl-2-pyridyl R1=4,6-dimethyl-2-pyridyl
Scheme-7
CNBr
CSCl2
20
43
21
22  
It has been shown that o-aminobenzoylhydrazine reacted with (i) 1,1’-carbonyl- bis-
imidazole(a variation of the use of phosgene) to give oxadiazolinone(23)38 and (ii) 1,3 
dicyclohexylcarbodiimide and an isothiocyanate RNCS to give aminooxadiazole (24).39 
(Scheme-8) 
HN
O
NH2
NH2 N C N
O
NHN
O
NH2
O
NHN
NHR
NH2
RNCS
1, 1'-c
arbony
lbisim
idazol
e
23
24Scheme-8  
A variation of the oxidative cyclization of acyl-thiosemicarbazides to aminooxadia-
zoles.40A variation of the reaction of acylhydrazines and carbon disulfide forming oxa-
diazolinethiones, is the reaction of thiosemicarbazide (RNHCSNHNH2) with carbon oxy-
sulfide and benzyl chloride, which yields amino-oxadiazolyl thioethers(25).41 (Scheme-9) 
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3.4  AIM OF CURRENT WORK 
 
A large number of heterocyclic oxadiazole and related compounds have been reported for 
their anti-inflammatory activity. Some new work is also reported so far on the anti-
inflammatory activity. These results promoted us to synthesize the substituted 1-((5-
(Benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)amine. A series of 26, benzofuran bearing 
oxadiazole derivatives have been synthesized by treating different amines with benzofu-
ran containing 1,3,4-oxadiazole in DMF.  
 
3.5  REACTION SCHEME 
  
a) DMF,K2CO3, 110 °C 
b) NH2-NH2 , 0 °C 
c) DMF,TEA, ClCH2COCl, 0 °C  
d) POCl3 ,Reflux 
e) DMF, K2CO3, R1= Substituted amine 
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3.6  REACTION MECHANISM  
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3.7  EXPERIMENTAL 
 Preparation of Ethyl benzofuran-2-carboxylate 
Salisaldehyde (0.01 mole) was charged into 250 ml round bottom flask. 30 ml of DMF 
was added into the flask. Then 0.01 mole of ethylbromo acetate and K2CO3 (0.03 mole) 
was added. The reaction mixture was refluxed for 1.5 h at 110 °C on oil bath. The 
progress and the completion of the reaction were checked by TLC using hexane: ethyl 
acetate (9:1) as a mobile phase. After the reaction was completed, reaction mixture was 
poured into ice. Then product was extracted using ethyl acetate (50 ml × 3), the combined 
organic layer was washed using brine solution (20 ml × 2). The organic layer was dried 
on anhydrous sodium sulphate and the solvent was removed under reduced pressure to 
acquire the product in a viscous liquid form. Yield - 77 %, B.P.- 276 °C. 
 Preparation of Benzofuran-2-carbohydrazides  
Ethyl benzofuran-2-carboxylate (0.01 mole) was charged into 250 ml round bottom flask. 
15 ml of hydrazine hydrate was added drop wise at 0-5 °C in above flask. The progress 
and the completion of the reaction were checked by silica gel-G F254 thin layer chromato-
graphy using hexane: ethyl acetate (4: 6) as a mobile phase. After the reaction was com-
pleted, the mixture was stirred at room temperature to give benzofuran-2-carbohydrazide 
as a white colored shining product. M.P.-190-194 °C.  
 Preparation of N'-(2-chloroacetyl)benzofuran-2-carbohydrazide 
Benzofuran-2-carbohydrazides (0.01 mole), tri ethyl amine (0.02 mole) and DMF were 
taken in a flask and stirred continuously with mechanical stirring. Resulting mix was 
cooled at 0 °C then added drop wise chloracetyl chloride (0.02 mole). The reaction mix 
was stirred over night. The reaction was poured in to the ice and extracted with ethyl 
acetate. The organic layer was separated out and dried with sodium sulphate. The organic 
layer was evaporated under reduced pressure to give yellow oily compound. The 
compound was purified by column chromatography by silica gel 230-400 mash. TLC. 
(EtoAC: Hexane : 4:6). Yield : 65%. 
Note: The entire reaction was carried out under nitrogen atmosphere. 
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 Preparation of 2-(Benzofuran-2-yl)-5-(chloromethyl)-1,3,4-oxadiazole 
N'-(2-chloroacetyl) benzofuran-2-carbohydrazide (0.01mole), phosphorous oxychloride 
10 ml was charged into 250 ml round bottom flask and reflux for 10 h at 100 °C. The 
progress and the completion of the reaction were checked by TLC using hexane: ethyl 
acetate (4: 6) as a mobile phase. After completion of the reaction, reaction was poured in 
to ice to give solid 2-(Benzofuran-2-yl)-5-(chloromethyl)-1,3,4-oxadiazole. Yield : 72%. 
 General method for preparation of substituted 1-((5-(Benzofuran-2-yl)-1,3,4-
oxadiazol-2-yl)methyl)amine  
2-(Benzofuran-2-yl)-5-(chloromethyl)-1,3,4-oxadiazole (0.1 mole), anhydrous potassium 
carbonate (0.2 mole) and DMF were taken in flask and sitrred continuously with 
mechanical stirring. The substituted amine (0.1 mole) was added drop wise at room 
temperature, reaction mix was stirred for 12 h. The reaction was poured in to the ice to 
give solid title compound.The compound was recrystlized by ethanol. TLC. (EtoAC: 
Hexane : 3:7). Yield : 55-77%. 
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3.8  PHYSICAL DATA  
TABLE: 1  PHYSICAL DATA OF SUBSTITUTED 1-((5-(BENZOFURAN-2-
YL)-1,3,4-OXADIAZOL-2-YL)METHYL)AMINE  
Sr. No Structure M.F M.P. (°C) 
Rf 
value 
% 
Yield 
DPB-42 C16H17N3O2 180-182 0.46 67 
DPB-43 C15H15N3O3 224-226 0.52 63 
DPB-44 C15H16N4O2 192-194 0.44 48 
DPB-45 C16H18N4O2 244-246 0.48 58 
DPB-46 C17H20N4O2 198-200 0.40 53 
DPB-47 C22H22N4O2 202-204 0.54 68 
DPB-48 
N N
O
N
O
N
C21H20N4O2 188-190 0.50 47 
DPB-49 C15H15N3O2 224-226 0.52 58 
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DPB-50 C23H17N3O2 212-214 0.42 71 
DPB-51 
N N
O
N
O
C15H17N3O2 200-202 0.44 55 
DPB-52 C17H19N3O2 180-182 0.46 57 
DPB-53 C17H12ClN3O2 188-190 0.51 48 
DPB-54 
N N
O
HN
O
Cl
C17H12ClN3O2 208-210 0.51 59 
DPB-55 C18H15N3O2 222-224 0.49 57 
DPB-56 C18H15N3O2 238-240 0.45 46 
DPB-57 C17H12N4O4 192-194 0.48 49 
DPB-58 C17H12N4O4 189-191 0.42 61 
DPB-59 C18H15N3O3 198-200 0.49 53 
DPB-60 C18H15N3O3 220-222 0.50 46 
DPB-61 C17H12FN3O2 238-240 0.48 56 
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Rf value was calculated using solvent system, EtoAC: Hexane : 3:7. 
 
 
 
 
 
 
 
 
 
 
DPB-62 C17H11ClFN3O
2 
202-204 0.52 59 
DPB-63 C18H12F3N3O2 188-190 0.51 65 
DPB-64 C19H17N3O2 224-226 0.47 74 
DPB-65 C18H15N3O2 230-232 0.46 65 
DPB-66 C17H19N3O2 190-192 0.48 61 
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3.9  SPECTRAL STUDY 
 IR spectra 
Infra Red spectra were taken on Shimadzu FT-IR-8400 spectrometer using KBr pellet 
method. The characteristic aromatic group in 1,3,4-oxadiazol moiety is observed at 3010-
3090 cm-1. Secondary amine (> NH) observed a broad peak between 3200-3000 cm-1. 
Methylene group (>CH2) observed at 3000-2850 cm-1. Methyl (-CH3) observed at 1350 
cm-1. DPB-42 and DPB-61 of IR spectra are given on page no: - 110. 
 1H NMR spectra 
1H NMR spectra were recorded on a Bruker AC 400 MHz NMR spectrometer using 
TMS (Tetramethyl Silane) as an internal standard and DMSO-d6 & CDCl3 as a solvent. 
In the NMR spectra of 1-((5-(Benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)amine 
derivatives various proton values of methylene (-CH2), amine (-NH), methyl (-CH3) and 
aromatic protons (Ar-H) etc. were observed as under. 
The values for methylene (-CH2) proton is observed between 2.50-3.55 δ ppm. In some 
cases, the value of methylene proton differs to 4.20 and 4.43 δ ppm. The -NH protons of 
substituted aniline observed at 3.95-4.20 δ ppm. Aromatic protons shows the multiplet 
between  6.12-8.39 δ ppm. DPB-46, DPB-47, DPB-48 and Intermediate of 1H NMR 
spectra are given on page no: - 104 to 109. 
N N
O
N
O
N
1
2
3
4
5
6
78
9
10
3
4
 
 
1. The proton no.1 of methyl group gave a characteristic triplet at 0.98 δ ppm. 
2. The proton no.2 of methylene group gave a characteristic quartet at 2.33 δ ppm. 
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3. The proton no. 3 and 4 of piperazine eight protons which is attached with nitrogen 
atom gave a multiplet at 2.44 δ ppm- 2.59 δ ppm. it became a deshielded due to 
the nitrogen atom. 
4. The proton no.5 of methylene group gave a characteristic singlet at 3.88 δ ppm 
5. The proton no. 6 of benzofuran ring gave a characteristic singlet at 7.26 δ ppm. 
6. The aromatic ring of proton no. 10 gave a multiplet at 7.30 δ ppm. 
7. The aromatic ring of proton no. 8 and 9 gave a multiplet at 7.53 δ ppm -7.62 δ 
ppm. 
8. The aromatic ring of proton no. 7 gave a multiplet at 7.68 δ ppm. 
Thus, by observing and assigning the peaks in the NMR spectrum and by the cal-
culation of the J values for each of the above proton, the proposed structure for com-
pound DPB-46 was confirmed.  
 13C NMR spectra 
13C NMR spectra were recorded on a Bruker AC 400 MHz NMR spectrometer using 
DMSO-d6 & CDCl3 as a solvent. In the 13C NMR spectra of 1-((5-(Benzofuran-2-yl)-
1,3,4-oxadiazol-2-yl)methyl) amine derivatives various carbon values of methylene (-
CH2), keto (>C=O), methyl (-CH3) and aromatic carbon (Ar-H) etc. were observed as 
under. 
The values for methylene (-CH2) carbon is observed between 35-65 δ ppm. The >C=O 
carbon observed at 160-180 δ ppm. Aromatic carbon shows between  110-140 δ ppm. 
DPB-46, DPB-47, DPB-48 and Intermediate of 13C NMR spectra are given on page no: - 
104 to 109. 
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N N
O
N
O
N
1
2
3
4
5
67
89
10
17
16
11 12 13
14 15
 
1. The carbon no. 1 of methyl group, appear at 11.54 δ ppm. 
2. The carbon no. 2 and 5 of methylene group, appear at 40.24 δ ppm. 
3. The carbon no. 3, 4, 16 and 17 methyl groups, appear at 51.12 δ ppm- 52.06 δ 
ppm. 
4. The carbon no. 12 of benzofuran ring, appear at 155.02 δ ppm. 
5. The carbon no. 13 of benzofuran ring, appear at 140.01 δ ppm. 
6. The carbon no. 14 of oxadiazole ring, appear at 163.1 δ ppm. 
7. The carbon no. 15 of oxadiazole ring, appear at 157.7 δ ppm. 
8. The carbon no. 7, 8, 9, 10 and 11 of benzofuran ring, appear at 109.9 δ ppm- 
126.8 δ ppm. 
 
 Mass spectra 
The mass spectrum of compounds were recorded by Shimadzu GC-MS-QP-2010  
spectrometer. The mass spectrum of compounds was obtained by positive chemical 
ionization mass spectrometry. The molecular ion peak and the base peak in all 
compounds were clearly obtained in mass spectral study. The molecular ion peak (M+) 
values are in good agreement with molecular formula of all the compounds synthesized. 
DPB- 46, DPB-59 and DPB-61 of Mass spectra are given on page no.- 103 and 104. 
 Elemental analysis 
Elemental analysis of the synthesized compounds was carried out on Vario EL-III Carlo 
Erba 1108 model at Saurashtra University, Rajkot which showed calculated and found 
percentage values of Carbon, Hydrogen and Nitrogen in support of the structure of syn-
thesized compounds. The elemental analysis data are given for individual compounds. 
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3.10  SPECTRAL CHARACTERIZATION 
1-((5-(Benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)piperidine (DPB-42) 
IR (KBr) cm-1: 1639 (>C=N, str), 1087 (C-O-C), 2852 (>CH2 ,str), 1438 (>CH2 ,ban), 
3010 (=C-H, str), 3037 (Ar, C-H, str), 1564 (Ar, C=C, str). Mass: [m/z (%)], M. Wt.: 
283. Elemental analysis, Calculated: C, 67.83; H, 6.05; N, 14.83 Found: C, 67.79; H, 
6.10; N, 14.79. 
4-((5-(Benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)morpholine (DPB-43) 
IR (KBr) cm-1: 1625 (>C=N, str), 1087 (C-O-C), 2872 (>CH2 ,str), 1455 (>CH2 ,ban), 
3015 (=C-H, str), 3042 (Ar, C-H, str), 1513 (Ar, C=C, str). Mass: [m/z (%)], M. Wt.: 
285. Elemental analysis, Calculated: C, 63.15; H, 5.30; N, 14.73 Found: C, 63.10; H, 
5.28; N, 14.65. 
1-((5-(Benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)piperazine (DPB-44) 
IR (KBr) cm-1: 3496 (-NH), 1616 (>C=N, str), 1077 (C-O-C), 2871 (>CH2 ,str), 1445 
(>CH2 ,ban), 3010 (=C-H, str), 3036 (Ar, C-H, str), 1520 (Ar, C=C, str). Mass: [m/z 
(%)], M. Wt.: 284. Elemental analysis, Calculated: C, 63.37; H, 5.67; N, 19.71; 
Found: C, 63.23; H, 5.68; N, 19.61. 
1-((5-(Benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-4-methylpiperazine (DPB-45) 
IR (KBr) cm-1: 1618 (>C=N, str), 1080 (C-O-C), 2862 (>CH2 ,str), 1455 (>CH2 ,ban), 
3015 (=C-H, str), 3042 (Ar, C-H, str), 1526 (Ar, C=C, str), 1368 (-CH3, str.). Mass: [m/z 
(%)], M. Wt.: 298. Elemental analysis, Calculated: C, 64.41; H, 6.08; N, 18.78 Found: 
C, 64.32; H, 6.16; N, 18.71. 
1-((5-(Benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-4-ethylpiperazine (DPB-46) 
IR (KBr) cm-1: 1626 (>C=N, str), 1077 (C-O-C), 2878 (>CH2 ,str), 1463 (>CH2 ,ban), 
3026 (=C-H, str), 3047 (Ar, C-H, str), 1533 (Ar, C=C, str), 1374 (-CH3, str.). 1H NMR 
400 MHz: (DMSO-d6, δ ppm): 3.86 (s, 2H, -CH2), 2.31 (q, 2H, -CH2), 1.00 (t, 3H, -
CH3), 2.46 (m, 8H, -CH2), 7.26-7.71 (m, 5H, Ar-H). 13C NMR 400 MHz: (DMSO-d6, δ 
ppm): 11.5, 51.1, 51.5, 51.9, 52.0, 109.9, 111.4, 122.1, 123.7, 126.7, 126.8, 140.0, 155.0, 
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157.7, 163.1 Mass: [m/z (%)], M. Wt.: 312. Elemental analysis, Calculated: C, 65.37; 
H, 6.45; N, 17.94 Found: C, 65.42; H, 6.39; N, 17.88. 
1-((5-(Benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-4-benzylpiperazine (DPB-47) 
IR (KBr) cm-1: 1630 (>C=N, str), 1075 (C-O-C), 2885 (>CH2 ,str), 1471 (>CH2 ,ban), 
3025 (=C-H, str), 3052 (Ar, C-H, str), 1545 (Ar, C=C, str). 1H NMR 400 MHz: (DMSO-
d6, δ ppm): 3.50 (s, 2H, -CH2), 3.91 (s, 2H, -CH2), 2.39-2.61 (m, 8H, -CH2), 7.18-7.78 
(m, 10H, Ar-H) 13C NMR 400 MHz: (DMSO-d6, δ ppm): 30.5, 51.1, 52.2, 110.0, 
111.5,122.3,123.8, 126.6, 126.8, 126.9, 127.8, 128.6, 137.7, 140.0, 154.9, 157.6, 
163.2Mass: [m/z (%)], M. Wt.: 374. Elemental analysis, Calculated: C, 70.57; H, 
5.92; N, 14.96 Found: C, 70.49; H, 5.86; N, 14.90. 
1-((5-(Benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-4-phenylpiperazine (DPB-48) 
IR (KBr) cm-1: 1637 (>C=N, str), 1076 (C-O-C), 2882 (>CH2 ,str), 1475 (>CH2 ,ban), 
3023 (=C-H, str), 3056 (Ar, C-H, str), 1547 (Ar, C=C, str). 1H NMR 400 MHz: (DMSO-
d6, δ ppm): 3.99 (s, 2H, -CH2), 2.77 (m, 4H, -CH2), 3.19 (m, 4H, -CH2), 6.76-7.78 (m, 
10H, Ar-H) 13C NMR 400 MHz: (DMSO-d6, δ ppm): 30.5, 48.3, 51.1, 52.2, 110..1, 
111.5, 115.5, 119.0, 122.3, 123.8, 126.8, 128.6, 140.0, 150.7, 155.0, 157.7, 163.2 Mass: 
[m/z (%)], M. Wt.: 360. Elemental analysis, Calculated: C, 69.98; H, 5.59; N, 15.55 
Found: C, 69.92; H, 5.65; N, 15.65. 
2-(Benzofuran-2-yl)-5-((pyrrolidin-1-yl)methyl)-1,3,4-oxadiazole (DPB-49) 
IR (KBr) cm-1: 1640 (>C=N, str), 1078 (C-O-C), 2890 (>CH2 ,str), 1463 (>CH2 ,ban), 
3052 (=C-H, str), 3045 (Ar, C-H, str), 1565 (Ar, C=C, str). Mass: [m/z (%)], M. Wt.: 
269. Elemental analysis, Calculated: C, 66.90; H, 5.61; N, 15.60 Found: C, 66.98; H, 
5.55; N, 15.65. 
N-((5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-N-phenylbenzenamine (DPB-50) 
IR (KBr) cm-1: 1639 (>C=N, str), 1068 (C-O-C), 2896 (>CH2 ,str), 1455 (>CH2 ,ban), 
3052 (=C-H, str), 3039 (Ar, C-H, str), 1564 (Ar, C=C, str). Mass: [m/z (%)], M. Wt.: 
367.  Elemental analysis, Calculated: C, 75.19; H, 4.66; N, 11.44 Found: C, 75.22; H, 
4.62; N, 11.48. 
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N-((5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-N-ethylethanamine (DPB-51) 
IR (KBr) cm-1: 1652 (>C=N, str), 1087 (C-O-C), 2879 (>CH2 ,str), 1462 (>CH2 ,ban), 
3041 (=C-H, str), 3062 (Ar, C-H, str), 1574 (Ar, C=C, str), 1361 (-CH3, str.). Mass: [m/z 
(%)], M. Wt.: 271. Elemental analysis, Calculated: C, 66.40; H, 6.32; N, 15.49 
Found: C, 66.38; H, 6.35; N, 15.57. 
1-((5-(Benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-2-methylpiperidine (DPB-52) 
IR (KBr) cm-1: 1651 (>C=N, str), 1089 (C-O-C), 2883 (>CH2 ,str), 1450 (>CH2 ,ban), 
3049 (=C-H, str), 3063 (Ar, C-H, str), 1579 (Ar, C=C, str), 1370 (-CH3, str.). Mass: [m/z 
(%)], M. Wt.: 297. Elemental analysis, Calculated: C, 68.67; H, 6.44; N, 14.13Found: 
C, 68.60; H, 6.38; N, 14.11. 
N-((5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-2-chlorobenzenamine (DPB-53) 
IR (KBr) cm-1: 1655 (>C=N, str), 1098 (C-O-C), 2879 (>CH2 ,str), 1462 (>CH2 ,ban), 
3074 (=C-H, str), 3068 (Ar, C-H, str), 1545 (Ar, C=C, str), 3352 (N-H, str), 1626 (N-H, 
ban). Mass: [m/z (%)], M. Wt.: 325. Elemental analysis, Calculated: C, 62.68; H, 
3.71; N, 12.90 Found: C, 62.65; H, 3.65; N, 12.89. 
N-((5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-3-chlorobenzenamine (DPB-54) 
IR (KBr) cm-1: 1656 (>C=N, str), 1087 (C-O-C), 2888 (>CH2 ,str), 1452 (>CH2 ,ban), 
3044 (=C-H, str), 3068 (Ar, C-H, str), 1585 (Ar, C=C, str), 3351 (N-H, str), 1627 (N-H, 
ban).) Mass: [m/z (%)], M. Wt.: 325. Elemental analysis, Calculated: C, 62.68; H, 
3.71; N, 12.90 Found: C, 62.65; H, 3.68; N, 12.75. 
N-((5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-2-methylbenzenamine (DPB-55) 
IR (KBr) cm-1: 1656 (>C=N, str), 1087 (C-O-C), 2888 (>CH2 ,str), 1452 (>CH2 ,ban), 
3044 (=C-H, str), 3068 (Ar, C-H, str), 1585 (Ar, C=C, str), 3351 (N-H, str), 1627 (N-H, 
ban), 1372 (-CH3, str.). Mass: [m/z (%)], M. Wt.: 305. Elemental analysis, Calculated: 
C, 70.81; H, 4.95; N, 13.76 Found: C, 70.96; H, 4.82; N, 13.71. 
N-((5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-3-methylbenzenamine (DPB-56) 
IR (KBr) cm-1: 1646 (>C=N, str), 1095 (C-O-C), 2886 (>CH2 ,str), 1445 (>CH2 ,ban), 
3045 (=C-H, str), 3072 (Ar, C-H, str), 1581 (Ar, C=C, str), 3358 (N-H, str), 1630 (N-H, 
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ban), 1352 (-CH3, str.). Mass: [m/z (%)], M. Wt.: 305. Elemental analysis, Calculated: 
C, 70.81; H, 4.95; N, 13.76 Found: C, 70.95; H, 4.83; N, 13.75. 
N-((5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-3-nitrobenzenamine (DPB-57) 
IR (KBr) cm-1: 1653 (>C=N, str), 1115 (C-O-C), 2872 (>CH2 ,str), 1450 (>CH2 ,ban), 
3052 (=C-H, str), 3081 (Ar, C-H, str), 1582 (Ar, C=C, str), 3351 (N-H, str), 1632 (N-H, 
ban), 1515 (-NO2, str). Mass: [m/z (%)], M. Wt.: 336. Elemental analysis, Calculated: 
C, 60.71; H, 3.60; N, 16.66 Found: C, 60.79; H, 3.45; N, 16.62. 
N-((5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-4-nitrobenzenamine (DPB-58) 
IR (KBr) cm-1: 1651 (>C=N, str), 1086 (C-O-C), 2870 (>CH2 ,str), 1455 (>CH2 ,ban), 
3059 (=C-H, str), 3089 (Ar, C-H, str), 1579 (Ar, C=C, str), 3356 (N-H, str), 1636 (N-H, 
ban), 1525 (-NO2, str). Mass: [m/z (%)], M. Wt.: 336. Elemental analysis, Calculated: 
C, 60.71; H, 3.60; N, 16.66 Found: C, 60.79; H, 3.45; N, 16.62. 
N-((5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-2-methoxybenzenamine (DPB-
59) 
IR (KBr) cm-1: 1655 (>C=N, str), 1089 (C-O-C), 2873 (>CH2 ,str), 1454 (>CH2 ,ban), 
3062 (=C-H, str), 3089 (Ar, C-H, str), 1589 (Ar, C=C, str), 3358 (N-H, str), 1636 (N-H, 
ban), 1358 (-CH3, str.). Mass: [m/z (%)], M. Wt.: 321. Elemental analysis, Calculated: 
C, 67.28; H, 4.71; N, 13.08 Found: C, 67.32; H, 4.75; N, 13.10. 
N-((5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-3-methoxybenzenamine (DPB-
60) 
IR (KBr) cm-1: 1649 (>C=N, str), 1093 (C-O-C), 2883 (>CH2 ,str), 1452 (>CH2 ,ban), 
3063 (=C-H, str), 3087 (Ar, C-H, str), 1579 (Ar, C=C, str), 3362 (N-H, str), 1630 (N-H, 
ban), 1358 (-CH3, str.). Mass: [m/z (%)], M. Wt.: 321. Elemental analysis, Calculated: 
C, 67.28; H, 4.71; N, 13.08 Found: C, 67.32; H, 4.75; N, 13.11. 
N-((5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-3-fluorobenzenamine (DPB-61) 
IR (KBr) cm-1: 1636 (>C=N, str), 1087 (C-O-C), 2910 (>CH2 ,str), 1440 (>CH2 ,ban), 
3069 (=C-H, str), 3032 (Ar, C-H, str), 1564 (Ar, C=C, str), 3335 (N-H, str), 1631 (N-H, 
ban),1015 (>C-F, str). Mass: [m/z (%)], M. Wt.: 309. Elemental analysis, Calculated: 
C, 66.02; H, 3.91;N, 13.59 Found: C, 66.10; H, 3.98;N, 13.63. 
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N-((5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-3-chloro-4-fluorobenzenamine 
(DPB-62) 
IR (KBr) cm-1: 1637 (>C=N, str), 1099 (C-O-C), 2879 (>CH2 ,str), 1462 (>CH2 ,ban), 
3069 (=C-H, str), 3092 (Ar, C-H, str), 1597 (Ar, C=C, str), 3383 (N-H, str), 1630 (N-H, 
ban),1026 (>C-F, str), 652 (>C-Cl, str). Mass: [m/z (%)], M. Wt.: 343. Elemental 
analysis, Calculated: C, 59.40; H, 3.23; N, 12.22 Found: C, 59.45; H, 3.15; N, 12.29. 
N-((5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-3-(trifluoromethyl)benzenamine 
(DPB-63) 
IR (KBr) cm-1: 1639 (>C=N, str), 1119 (C-O-C), 2880 (>CH2 ,str), 1462 (>CH2 ,ban), 
3076 (=C-H, str), 3099 (Ar, C-H, str), 1589 (Ar, C=C, str), 3389 (N-H, str), 1638 (N-H, 
ban),1029 (>C-F, str). Mass: [m/z (%)], M. Wt.: 359. Elemental analysis, Calculated: 
C, 60.17; H, 3.37; N, 11.69 Found: C, 60.17; H, 3.37; N, 11.69. 
N-((5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-2,4-dimethylbenzenamine (DPB-
64) 
IR (KBr) cm-1: 1642 (>C=N, str), 1109 (C-O-C), 2881 (>CH2 ,str), 1461 (>CH2 ,ban), 
3078 (=C-H, str), 3089 (Ar, C-H, str), 1599 (Ar, C=C, str), 3345 (N-H, str), 1640 (N-H, 
ban), 1359 (-CH3, str.). Mass: [m/z (%)], M. Wt.: 319. Elemental analysis, Calculated: 
C, 71.46; H, 5.37; N, 13.16 Found: C, 71.40; H, 5.35; N, 13.14. 
N-((5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)(phenyl)methanamine (DPB-65) 
IR (KBr) cm-1: 1649 (>C=N, str), 1109 (C-O-C), 2871 (>CH2 ,str), 1451 (>CH2 ,ban), 
3086 (=C-H, str), 3095 (Ar, C-H, str), 1587 (Ar, C=C, str), 3346 (N-H, str), 1648 (N-H, 
ban). Mass: [m/z (%)], M. Wt.: 305. Elemental analysis, Calculated: C, 70.81; H, 
4.95; N, 13.76 Found: C, 70.78; H, 4.91; N, 13.78. 
N-((5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)cyclohexanamine (DPB-66) 
IR (KBr) cm-1: 1645 (>C=N, str), 1108 (C-O-C), 2873 (>CH2 ,str), 1456 (>CH2 ,ban), 
3075 (=C-H, str), 3010 (Ar, C-H, str), 1589 (Ar, C=C, str), 3353 (N-H, str), 1650 (N-H, 
ban). Mass: [m/z (%)], M. Wt.: 297. Elemental analysis, Calculated: C, 68.67; H, 
6.44; N, 14.13 Found: C, 68.78; H, 6.36; N, 14.10. 
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3.11  CONCLUSION 
 
Total 25 derivatives of substituted 1-((5-(Benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl) 
amine were synthesized. All the newly synthesized compounds were characterized by IR, 
1H NMR, 13C NMR, Mass spectral data and elemental analysis. The synthesized com-
pounds were screened for anti-inflammatory and anti-cancer activity and results are 
awaited. 
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3.12  REPRESENTATIVE SPECTRUM  
Mass spectrum of N-((5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-2-
methoxybenzenamine (DPB-59) 
 
Mass spectrum of N-((5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-3-
fluorobenzenamine (DPB-61) 
 
N N
O
HN
O
H3CO
Mol. Wt.: 321.33
N N
O
HN
O
F
Mol. Wt.: 309.29
 
Chapter-3                                                       1,3,4-Oxadiazole derivatives 
 
Department of Chemistry, Saurashtra University, Rajkot   104 
 
Mass spectrum of 1-((5-(Benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-4-
ethylpiperazine (DPB-46) 
 
1H NMR spectrum of 2-(Benzofuran-2-yl)-5-(chloromethyl)-1,3,4-oxadiazole (In-
termediate) 
 
N N
O
N
O
N
Mol. Wt.: 312.37
N N
O
O Cl
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1H NMR spectrum of 2-(Benzofuran-2-yl)-5-((4-phenylpiperazin-1-yl)methyl)-1,3,4-
oxadiazole (DPB-
N N
O
N
O
N
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13C NMR spectrum of 2-(Benzofuran-2-yl)-5-((4-phenylpiperazin-1-yl)methyl)-1,3,4-
oxadiazole 
 
N N
O
N
O
N
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1H NMR spectrum of 1-((5-(Benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-4-
benzylpiperazine (DPB-47) 
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13C NMR spectrum of 1-((5-(Benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-4-
benzylpiperazine (DPB-47) 
 
1H NMR spectrum of 1-((5-(Benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-4-
ethylpiperazine (DPB-46) 
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13C NMR spectrum of 1-((5-(Benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-4-
ethylpiperazine (DPB-46) 
 
 
 
N N
O
N
O
N
 
Chapter-3                                                       1,3,4-Oxadiazole derivatives 
 
Department of Chemistry, Saurashtra University, Rajkot   110 
 
IR spectrum of 1-((5-(Benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)piperidine 
(DPB-42) 
 
IR spectrum of N-((5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)methyl)-3-
fluorobenzenamine (DPB-61) 
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4.1     INTRODUCTION 
 
Valproic acid is simple branched chain carboxylic acid used in epilepsy. Valproic acid 
increases GABA (γ-amino butyric acid) synthesis and release and potentiates by this 
mechanism GABA ergic transmission in specific brain regions. Valproic acid also 
reduces the release of excitatory amino acid β-hydroxy butyric acid and attenuates 
neuronal excitation mediated by activation of N-methyl-D-aspartames glutamate 
receptors. Valproic acid is a broad-spectrum antiepileptic drug effective against all 
seizure types. 
 
Valproic acid (chemical name 2-propylvaleric acid) was first synthesized in 1882 by 
Burton as an analogue of valeric acid, found naturally in valerian. A clear liquid fatty 
acid at room temperature, for many decades its only use was in laboratories as a 
"metabolically inert" solvent for organic compounds. In 1962, the French researcher 
Pierre Eymard serendipitously discovered the anticonvulsant properties of valproic 
acid while using it as a vehicle for a number of other compounds that were being 
screened for anti-seizure activity. He found that it prevented pentylenetetrazol-
induced convulsions in rodents. Since then it has also been used for migraine and 
bipolar disorder.  
 
4.2  VALPROATE: PAST, PRESENT, AND FUTURE   
 
Preclinical studies have been carried out during the past four decades to investigate 
the different mechanisms of action of valproate (VPA). The mechanisms of VPA 
which seem to be of clinical importance include increased GABA ergic activity, 
reduction in excitatory neurotransmission, and modification of monoamines. These 
mechanisms are discussed in relation to the various clinical uses of the drug. VPA is 
widely used as an antiepileptic drug with a broad spectrum of activity. In patients, 
VPA possesses efficacy in the treatment of various epileptic seizures such as absence, 
myoclonic, and generalized tonic-clonic seizures. It is also effective in the treatment 
of partial seizures with or without secondary generalization and acutely in status 
epileptics. The pharmacokinetic aspects of VPA and the frequent drug interactions 
between VPA and other drugs are discussed. The available methods for the 
determination of VPA in body fluids are briefly evaluated. At present, investigations 
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and clinical trials are carried out and evaluated to explore the new indications for 
VPA in other conditions such as in psychiatric disorders, migraine and neuropathic 
pain. Furthermore, the toxicity of VPA, both regarding commonly occurring side 
effects and potential idiosyncratic reactions are described. Derivatives of VPA with 
improved efficacy and tolerability are in development.  
 
4.3  CHEMICAL STRUCTURE OF VALPROIC ACID AND ITS    
DERIVATIVES 
  
Molecular formula of valproic acid is C8H16O2 and molecular weight is 144.2. The 
derivatives of valproic acid are Sodium valproate molecular formula is C8H15NaO2 
and molecular weight is 166.2, Semi sodium valproate molecular formula is 
C16H31NaO4 and molecular weight is 310.4, Valproate pivoxil molecular formula is 
C14H26O4 and molecular weight is 258.4, Valpromide molecular formula is C8H17NO 
and molecular weight is 143.2. 
 
Chemical names of Valproic acid: 
2-Propylpentanoic acid, 2-Propylvaleric acid, Di-n-dipropylacetic acid 
Chemical names of Sodium valproate: 
Sodium 2-propylvalerate, Sodium 2-propylpentanoate 
Chemical names of Semi sodium valproate: 
2-Propylvaleric acid-sodium 2-propylvalerate, Sodium hydrogen bis(2-propylvalerate) 
Chemical names of Valproate pivoxil: 
Hydroxymethyl 2-propylvalerate pivalate 
Chemical names of Valpromide: 
Dipropylacetamide, 2-Propylvaleramide 
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4.4  PHYSICAL PROPERTIES OF VALPROIC ACID 
  
Valproic acid is colorless to pale yellow viscous liquid. It is slightly soluble in water 
(1.2 mg/mL); fully soluble in acetone, chloroform, ether and methyl alcohol. Valproic 
acid is stored in airtight containers and is sensitive to light. Valproic acid capsules 
should be stored at 15 to 30 °C and freezing should be avoided. 
 
4.5  USES OF VALPROIC ACID 
  
Valproic acid is used solely or in combination with other anticonvulsants in the 
treatment of simple (petit mal) and complex absence seizures. Valproate may be 
effective against myoclonic and atonics seizures in young children. 
 
 
4.6  SYNTHESIS OF VALPROIC ACID 
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4.7 MECHANISM ACTION OF VALPROIC ACID   
 
Valproic acid (VPA) is indicated for the treatment of epilepsy and bipolar disorder 
and in the prevention of migraine headaches. VPA has also become more widely 
prescribed due to several off-label indications such as in the treatment of neuropathic 
pain and cancer.1,2 Despite VPA being well tolerated and having a low incidence of 
serious side effects, one concern with VPA therapy is weight gain. A prospective 
study identified that 37% of female patients with epilepsy developed obesity, as 
defined as a body mass index (BMI) greater than 25, after 1 yr of treatment with 
VPA.3 Numerous retrospective and cross-sectional analyses also report that treatment 
with VPA is associated with a significant increase in weight ranging from 5 to 49 
kg.4,5,6,7 Studies examining VPA-induced weight gain have been conducted 
predominantly in adult women because VPA can induce a number of reproductive 
endocrine abnormalities that include hyperandrogenism, menstrual disturbances, 
weight gain, and/or polycystic ovaries.8,9,10 Fifty-two percent of males treated with 
VPA, however, also have BMI scores within the obesity category,11 and youth and 
adolescents treated with VPA are reported to have BMI scores over expected age 
norms.12,13,14 Similarly, a prospective double-blind comparison of the incidence and 
magnitude of weight gain in patients receiving VPA. Lamotrigine monotherapy 
demonstrated that weight gain was greater for those patients treated with VPA and 
was significant within 10 wk of treatment onset.15,16 Weight gain associated with VPA 
treatment is of great concern due to its physical and psychological consequences.17 
Notably, obesity leads to increase risk for numerous other diseases, such as diabetes 
mellitus, coronary heart disease,18 and increased noncompliance with 
pharmacotherapy in psychiatric patients.19  
 
The mechanism underlying VPA-induced weight gain has not been elucidated. Age, 
gender, medical condition, dose and serum concentrations of VPA and family history 
of body weight problems are not significantly correlated with the gain in weight 
associated with VPA treatment.20,21 In attempts to generate animal models of VPA-
induced weight gain, VPA has been shown to induce a significant increase in body 
weight in female rhesus monkeys;22 however, we and others have demonstrated that 
VPA does not cause weight gain in rodents.23,24,25 The etiology of VPA-induced 
weight gain is most likely multifactorial because weight is the output of energy 
homeostasis controlled by many organs that produce and secrete a variety of appetite-
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regulating peptides and cytokines that act within the hypothalamus.26 VPA treatment 
in humans increases the serum level of two hormones, leptin and insulin, which are 
produced by the adipose tissue and pancreatic β-cells, respectively. After VPA 
treatment for 1 yr, 37% of female patients with epilepsy who developed obesity had a 
1.8-fold increase in fasting serum insulin and 3.4-fold increase in serum leptin levels. 
Similarly, in women receiving VPA for treatment of bipolar disorder, insulin and 
leptin levels were significantly elevated when compared with women receiving 
lithium.27 High levels of serum leptin are commonly associated with obesity and could 
represent a state of leptin resistance.26,28 The increase in serum leptin associated with 
weight gain after VPA treatment may be a consequence of the increase in adipose 
tissue; however, it is also possible that VPA may have a direct effect on leptin 
secretion from adiposities or may alter leptin signaling and decrease negative 
feedback. VPA has been shown to have direct effects on hormone secretion from 
other endocrine cells. For example, an ex vivo study using human pancreatic islet cells 
has shown that VPA can directly increase insulin release.29 Moreover, VPA can also 
potentiate androgen production from ovarian theca cells.30 We previously 
demonstrated that VPA inhibited mouse 3T3-L1 and human preadipocyte 
differentiation.31 Treatment with VPA during adiposeness reduced the protein levels 
for several key adipocyte-specific transcription factors, including CCAAT/enhancer 
binding protein (C/EBP)-α, peroxisome proliferators-activated receptor (PPAR)-γ, and 
steroid regulatory element binding protein (SREBP) 1a.32 The present work 
demonstrates that treatment with VPA in mature adiposities significantly reduces 
leptin mRNA levels and secretion of the leptin protein in a dose and time-dependent 
manner. These findings were paradoxical because treatment of patients with VPA is 
associated with increased serum leptin levels. The reduction in leptin secretion from 
adiposities was not accompanied by alterations in glucose uptake or altered 
intracellular free fatty acid levels, which are known regulators of leptin secretion. In 
addition, C/EBP α, PPAR γ, or SREBP1a protein levels did not change with VPA 
treatment, suggesting the levels of these transcription factors are not responsible for 
the effect of VPA on leptin expression. Evidence from experiments using actinomycin 
D (ActD) or cyclohexamide (CHX) show that VPA does not promote degradation of 
leptin mRNA; however, VPA can alter leptin transcription through an unknown 
mechanism independent of new protein synthesis. These results show that VPA can 
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have direct effects on adiposities that may contribute to altered energy balance in 
patients treated with VPA. 
 
4.8 ANTI-CANCER ACTIVITY OF VALPROIC ACID  
 
The short chain fatty acid valproic acid (VPA, 2-propylpetanoic acid) is approved for 
the treatment of epilepsia, bipolar disorders and migraine and clinically used for 
schizophrenia. In 1999, the first clinical anti-cancer trial using VPA was initiated. 
Currently, VPA is examined in numerous clinical trials for different leukemia’s and 
solid tumor entities. In addition to clinical assessment, the experimental examination 
of VPA as anti-cancer drug is ongoing and many questions remain unanswered. 
Although other mechanisms may also contribute to VPA-induced anti-cancer effects, 
inhibition of histone deacetylases appears to play a central role.  
4.9 THE SECOND GENERATION TO VALPROIC ACID (VPA) 
 
Valproic acid, one of the established AEDs (Anti epilepsy drugs), is in animal models 
the least potent of the major AEDs. However, due to its wide spectrum of antiepileptic 
activity, VPA is the most prescribed AED.33,34 Valproic acid is also an effective (and 
FDA-approved) drug in migraine prophylaxis and in the treatment of bipolar disorder.  
 
Valproic acid is a simple molecule (isooctanoic acid)35 and, thus, a useful, cheap, and 
readily available starting material for synthesizing an array of derivatives that can 
become CNS-active follow-up compounds to VPA. We believe that novel chemical 
modifications and further development of specific VPA analogues and derivatives 
will show promising potential in the areas of epilepsy, pain, bipolar disorder, and 
other related neurological diseases. As VPA is the least potent among the established 
AEDs, it is possible to develop VPA analogues that will be significantly more potent 
than the parent compound and will also be nonteratogenic.  
 
There are numerous reports defining the strict structural requirements for the 
teratogenicity of VPA and its structurally related compounds. 36 Structure-activity 
relationship studies conducted in mice strains prone to VPA-associated teratogenicity 
indicate that to be teratogenic, and to cause neural tube defects in mice embryos, VPA 
analogues and derivatives should contain a tertiary carbon bound to a carboxylic 
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group, a hydrogen atom, and two alkyl chains. A VPA derivative lacking any one of 
these structural requirements has the potential to become a nonteratogenic entity.37 
For example, the corresponding CNS-active amide of VPA valpromide (VPD) that 
has a carboxamide moiety instead of a carboxylic group is not teratogenic. Similarly, 
the active metabolite of VPA is 2-ene-VPA, which does not have an α-hydrogen to 
the carboxylic moiety, is also nonteratogenic.38 Valpromide and 2-ene-VPA are potent 
anticonvulsant compounds that may represent a novel type of second-generation VPA 
drug. However, as their fraction metabolized to VPA in humans is greater than 90% 
(for VPD) and approximately 20% (for 2-ene-VPA), their lack of teratogenicity does 
not offer a clinical advantage over VPA. 
 
Unlike teratogenicity, the current thinking on VPA induced hepatotoxicity 
(microvesicular steatosis) is that it is not caused by the parent compound but primarily 
by VPA metabolite(s) with a terminal double-bond: 4-ene-VPA and 2,4-diene-VPA. 
These metabolites are further biotransformed to chemically reactive intermediates that 
bind to cellular macromolecules and enzymes involved in the metabolism of fatty 
acids. The first step in this cascade is the formation of an acyl-coenzyme A (CoA) 
thioester leading to depletion of CoA in the liver and, consequently, to 
hepatotoxicity.39,42 Designing substituted aliphatic and alicyclic VPA analogues and α 
and β substituted VPA derivatives (amides) to block the formation of these two 
metabolites should prevent, or at least minimize, the VPA-induced hepatotoxicity.43,45 
 
Structure–activity relationship studies mapped the structural elements of the VPA 
molecules responsible for the anticonvulsant activity.46 Subsequent studies showed 
that constitutional isomers of VPA, such as valnoctic acid (VCA), propylisopropyl 
acetic acid (PIA), or diisopropylacetic acid (DIA), were less active as anticonvulsants 
than VPA. However, their respective corresponding amides, 
propylisopropylacetamide (PID) and diisopropylacetamide (DID), are more potent 
than VPA. Unlike valproyl esters, VPA amide derivatives act as drugs on their own 
and not as prodrugs to their corresponding acids.47 Recent SAR data indicate that a 
pharmacokinetic-based design is an attractive and feasible approach for the 
development of nonteratogenic and nonhepatotoxic CNS-active second generation to 
VPA drugs. 
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4.10  AIM OF CURRENT WORK 
Over and above, the known antiepileptic properties of valproic acids and its salt, 
renewed interest of these molecules in anticancer1 and antiviral2 therapy has led wide 
interest in newer derivatives of these molecules.  
Currently, the leading compounds that are second generation to VPA can be divided 
into three groups (Figs.  1, 2, and 3) 1) Alkyl analogues of VPA and their amide 
derivatives, including chiral and achiral constitutional isomers of VPD (Fig. 1) 2) 
Amide derivatives of TMCA, a cyclopropyl analogue of VPA (FIG. 2) 3) Conjugation 
products between VPA and neuroinhibitory amino acids: GABA, glycine, taurine, and 
their corresponding amides (Fig. 3). Some valproic acid drugs & derivatives under 
preclinical/phase clinical trials.48,49 
 
FIG. 1. Valproic acid (VPA), its cyclopropyl analogue 2,2,3,3 tetramethylcyclopropanecarboxylic acid 
(TMCA) and their corresponding amides valpromide (VPD) and 2,2,3,3–
tetramethylcyclopropanecarboxamide (TMCD). FIG. 2. Chemical structures of CNS-active amides of 
valproic acid (VPA) analogues with the potential to become second-generation VPA drugs. 
Valnoctamide (VCD), propylisopropylacetamide (PID), di-isopropylacetamide (DID), N-methyl-
2,2,3,3-tetramethylcylclopropanecarboxamide (MTMCD), 2,2,3,3-tetramethylcyclopropylcarbonyl 
urea (TMC-urea), N-methoxy–2,2,3,3-tetramethylcylclopropanecarbonylurea (OM-TMCD), and 
isovaleramide (NPS 1776). * Indicates the chiral center. FIG. 3. Valrocemide and conjugation products 
between valproic acid and neuroinhibitory amino acids and their corresponding amides. 
                                                            
1 Current Pharmaceutical Design, 2007, 13(33), 3378-3393. 
2 Clin Pharmacokinet, 1996 , 30(5), 385-401. 
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In the current chapter, the valproic ‘Core’ structure was used as a starting material to 
synthesize valproic acid containing thiazole derivatives. The reaction of valproate 
with hydrazine hydrates and followed by chloroacetyal chloride and thiourea afforde 
the desired substituted thiazole derivatives. 
 
4.11  REACTION SCHEME 
 
 
a) CH3OH, gla.CH3COOH, 60-70 °C 
b) NH2-NH2, 110 °C 
c) DMF,TEA, ClCH2COCl, 0-5 °C 
d) (i) Thiourea, CH3OH, 65 °C 
(ii) Thiourea derivatives, CH3OH, 65 °C 
e) DMF,TEA, Substituted acid chloride, 0-5 °C 
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4.12  REACTION MECHANISM  
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4.13  EXPERIMENTAL 
 Preparation of Methyl 2-propyl pentanoate 
2-Propyl pentanoic acid (0.01 mole) was charged into 250 ml round bottom flask. 15 
ml of methanol was added into above flask. 3-4 drops of Con. sulphuric acid was 
added as a catalyst. The reaction mixture was refluxed for 12-14 h on water bath. The 
progress and the completion of the reaction were checked by silica gel-G F254 thin 
layer chromatography using hexane: ethyl acetate (4: 6) as a mobile phase. After the 
reaction was completed, excess of methanol was removed under reduced pressure. 
The separated product was extracted using ethyl acetate (30 ml × 3), the combined 
organic layer was washed using 5% sodium bicarbonate solution (20 ml × 2) followed 
by water (20 ml × 2). The organic layer was dried on anhydrous sodium sulphate and 
the solvent was removed under reduced pressure to acquire the product in a viscous 
liquid form. Yield - 90 %, B. P. - 170-172 °C.1 
1 I. Dostovalova; Organic Magnetic Resonance 1983, 21(1), 111-19. 
 
 Preparation of 2-Propyl pentanohydrazide 
Methyl 2-propylpentanoate (0.01 mole) was charged into 250 ml round bottom flask. 
15 ml of hydrazine hydrate was added into above flask. The reaction mixture was 
refluxed on water bath for 12-14 h. The progress and the completion of the reaction 
were checked by silica gel-G F254 thin layer chromatography using hexane: ethyl 
acetate (4: 6) as a mobile phase. After the reaction to be completed, the mixture was 
cooled to room temperature to give 2-propylpentanohydrazide as a white colored 
shining fluffy product. Yield - 60 %, M. P. - 124-126 °C. 2  
2 Benoit-Guyod, L. Jean; Chemica Therapeutica 1968, 3(5), 336-42. 
 Preparation of N'-(2-chloroacetyl)-2-propyl pentanehydrazide 
2-Propylpentanohydrazide (0.01 mole) was charged in 10 ml of tetrahydrofuran into 
250 ml round bottom flask. Then add triethylamine (0.015 mole) and chloroacetyl 
chloride (0.01 mole) at 0-5 °C. The reaction mixture was stirred at room temperature 
overnight. The progress and the completion of the reaction were checked by silica gel-
G F254 thin layer chromatography using toluene: ethyl acetate (4: 6) as a mobile phase. 
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After completion of the reaction, the reaction mixture was poured into crushed ice. N'-
(2-chloroacetyl)-2-propylpentanehydrazide A brown colored solid product.  
Note: The entire reaction was carried out under nitrogen atmosphere. 
 General procedure of N'-(substituted 2-aminothiazol-4-yl)-2-
propylpentanehydrazide 
N'-(2-chloroacetyl)-2-propyl pentanehydrazide (0.01 mole) was charged into 250 ml 
round bottom flask. 10 ml of methanol was added to dissolve it. Then add 0.015 mole 
of substituted thiourea. Resulting reaction mixture was reflux at 2-3 h. The progress 
and the completion of the reaction were checked by silica gel-G F254 thin layer 
chromatography using toluene: ethyl acetate (3:7) as a mobile phase. After the 
reaction was complete the mixture was poured into crushed ice to give white solid 
compound. 
 General procedure of N'-(2-( substituted benzamido)thiazol-4-yl)-2-
propyl-pentanehydrazide 
N'-(2-aminothiazol-4-yl)-2-propylpentanehydrazide (0.01 mole) was charged into 250 
ml round bottom flask. 10 ml of tetrahydrofuran was added to dissolve it. Add 0.015 
mole of triethylamine as a catalyst then added 0.01 mole of substituted acid chlorides 
at 0-5 °C. The reaction mixture was stirred at RT overnight. The progress and the 
completion of the reaction were checked by silica gel-G F254 thin layer 
chromatography using toluene: ethyl acetate (3: 7) as a mobile phase. After the 
reaction was complete mixture poured into crushed ice. N'-(2-(substituted 
benzamido)thiazol-4-yl)-2-propylpentanehydrazide a brown colored solid product.  
Note: The entire reaction was carried out under nitrogen atmosphere. 
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4.14  PHYSICAL DATA  
TABLE: 1  PHYSICAL DATA OF N'-(2-(SUBSTITUTED BENZAMIDO) 
THIAZOL-4-YL)-2-PROPYLPENTANEHYDRAZIDE 
DERIVATIVES 
Sr. No Substituted M.F. M. P (oC) Rf value 
% 
Yield 
DPB-67 C11H20N4OS 150-152 0.32 81 
DPB-68 C12H22N4OS 163-165 0.38 75 
DPB-69 C13H22N4O2S 142-146 0.36 72 
DPB-70 C11H21N5OS 182-184 0.28 62 
DPB-71 C23H28N4OS 225-227 0.42 69 
DPB-72 C18H24N4O2S 189-191 0.38 72 
DPB-73 
 
C19H26N4O2S 195-197 0.35 67 
DPB-74 C19H26N4O2S 193-195 0.36 69 
DPB-75 C19H26N4O2S 197-199 0.35 73 
DPB-76 C18H23ClN4O2S 183-185 0.41 79 
DPB-77 C18H23ClN4O2S 180-182 0.39 75 
DPB-78 C18H23ClN4O2S 186-188 0.42 76 
DPB-79 
 
C18H23N5O4S 175-177 0.39 66 
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DPB-80 C18H23N5O4S 179-181 0.41 63 
DPB-81 C19H26N4O2S 196-198 0.35 70 
 
Rf value was calculated using solvent system, Toluene: Ethyl Acetate (3: 7). 
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4.15  SPECTRAL STUDY 
 IR spectra 
Infra Red spectra were taken on SHIMADZU FTIR-435 spectrometer using KBr 
pellet method. The characteristic carbonyl group of –CONH in valporic acid moiety 
was observed at 1690-1630 cm-1. Amine (>NH) observed a broad peak between 3200-
3000 cm-1. Methylene gp (>CH2) observed at 3000-2850 cm-1. Methyl  (-CH3) 
observed at 1350 cm-1.  DPB- 68 and DPB-69 of IR spectra are given on page no: - 
138 and 139. 
 1H NMR spectra 
1H NMR spectra were recorded on a Bruker AC 400 MHz FT-NMR spectrometer 
using TMS (Tetramethyl Silane) as an internal standard and DMSO-d6 & CDCl3 as a 
solvent. In the NMR spectra of N'-(2-(substituted benzamido) thiazol-4-yl)-2-
propylpentanehydrazide various proton values of methylene (-CH2), amine (-NH) and 
methyl (-CH3) etc. were observed as under. 
The values for methyl (-CH3) proton is observed between 0.8-1.3 δ ppm.The values 
for methylene (-CH2) proton is observed between 1.3-2.2 δ ppm. The -NH protons of 
amide group (>CONH)  at 7.0-11.0 δ ppm. The signal due to NH proton of amide 
group was observed at  10.0-10.5 δ ppm value. DPB-67 and DPB-69 of 1H NMR 
spectra are given on page no: - 135 to 138. 
 
1.  The proton no.11 of amine group gave a characteristic broad singlet at 5.38 δ 
ppm. 
2. The proton no.10 of thiazole ring gave a characteristic singlet at 3.88 δ ppm. 
3. Proton no. 1and 4 of propyl chain of two methyl group of six proton gave a 
multiplet at 0.85 δ ppm - 0.89 δ ppm. 
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4. Proton no. 2, 3, 5 and 6 of di-propyl chain gave a multiplet at 1.25 δ ppm - 
1.38 δ ppm.  It showed expanded spectra. 
5. Proton no. 7 of di-propyl chain gave a multiplet at 2.27 δ ppm-2.32 δ ppm. 
6. Two most deshielded proton no.8 and 9 of secondary amine in hydrazide 
linkage of two (-NH) group gave two separable singlet in the down field at 
7.91 δ ppm and 10.02 δ ppm respectively. 
Thus, by observing and assigning the peaks in the NMR spectrum and by the 
calculation of the J values for each of the above proton, the proposed structure for 
compound DPB-67 was confirmed.  
 13C NMR spectra 
13C NMR spectra were recorded on a Bruker AC 400 MHz FT-NMR spectrometer 
using DMSO-d6 & CDCl3 as a solvent. In the 13C NMR spectra of N'-(2-(substituted 
benzamido)thiazol-4-yl)-2-propylpentanehydrazide various carbon values of 
methylene (-CH2), keto (>C=O), methyl (-CH3) and aromatic carban (Ar-H) etc. were 
observed as under. The values for methylene (-CH2) carban is observed between δ 35-
65 ppm. The >C=O carban observed at 160-180 δ ppm. Aromatic carbon shows 
between  110-140 δ ppm. DPB-67 and DPB-69 of 13C NMR spectra are given on page 
no: - 135 to 138. 
 
1. The carbon no. 1 and 4 methyl group, appear at 13.7 δ ppm it shows in 
spectra. 
2. The carbon no. 2 and 5 methylene group, appear at 20.12 δ ppm.  
3. The carbon no. 3 and 6 methylene group, appear at 34.8 δ ppm.  
4. The carbon no. 7 appears at 43.55 δ ppm it shows in spectra. 
5. The carbon no. 8 appears at 176.6 δ ppm due to the effect of carbonyl group. 
6. The carbon no. 9 and 11 thiazole ring appear at 173.1 δ ppm due to the effect 
of nitrogen atom.  
7. The carbon no. 10 thiazole ring appears at 99.49 δ ppm.  
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 Mass spectra 
The mass spectrum of compounds were recorded by Shimadzu GC-MS-QP-2010  
spectrometer (EI method). The mass spectrum of compounds was obtained by positive 
chemical ionization mass spectrometry. The molecular ion peak and the base peak in 
all compounds were clearly obtained in mass spectral study. The molecular ion peak 
(M+) values are in good agreement with molecular formula of all the compounds 
synthesized. DPB- 67, DPB-68 and DPB-69 of Mass spectra are given on page no.- 
134 and 135. 
 Elemental analysis 
Elemental analysis of the synthesized compounds was carried out on Vario EL Carlo 
Erba 1108 model at Saurashtra University, Rajkot which showed calculated and 
found percentage values of Carbon, Hydrogen and Nitrogen in support of the structure 
of synthesized compounds. The elemental analysis data are given for individual 
compounds. 
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4.16 SPECTRAL CHARACTERIZATION 
N'-(2-aminothiazol-4-yl)-2-propylpentanehydrazide (DPB-67) 
IR (KBr) cm-1: 3446 (N-H str), 2956 (-CH3 str.), 2931 (-CH2 str.), 2874 (-CH3 str.), 
1640 (-CONH), 1608 (N-H bending), 1452 (-CH3 ben), 1367 (-CH2 ben). 1H NMR 
400 MHz: (DMSO-d6, δ ppm): 0.89 (m, 6H, -CH3), 1.32 (m, 6H, -CH2), 1.57 (m, 2H, 
-CH2), 2.29 (m, 1H, -CH), 3.88 (s, 1H, -CH), 5.38 (s, broad, 2H,-NH2), 7.91 (s, broad, 
1H,-NH), 10.02 (s, broad, 1H,-NH). 13C NMR 400 MHz: (DMSO-d6, δ ppm): 13.78, 
20.12, 34.85, 43.88, 99.49, 173.1, 176.6 Mass: [m/z (%)], M. Wt.: 256. Elemental 
analysis, Calculated: C, 51.53; H, 7.86; N, 21.85 Found: C, 51.59; H, 7.79; N, 21.70 
N'-(2-(methylamino)thiazol-4-yl)-2-propylpentanehydrazide (DPB-68) 
IR (KBr) cm-1: 3408 (N-H str), 2924 (-CH3 str.), 287 (-CH2 str.), 2818 (-CH3 str.), 
1653 (-CONH), 1602 (N-H bending), 1481 (-CH3 ben), 1369 (-CH2 ben).  Mass: [m/z 
(%)], M. Wt.: 270. Elemental analysis, Calculated: C, 53.30; H, 8.20; N, 20.72 
Found: C, 53.32; H, 8.28; N, 20.65 
N'-(2-acetamidothiazol-4-yl)-2-propylpentanehydrazide (DPB-69) 
IR (KBr) cm-1: 3489 (N-H str), 2963 (-CH3 str.), 2870 (-CH2 str.), 2775 (-CH3 str.), 
1664 (-CONH), 1631 (N-H bending), 1447 (-CH3 ben), 1371 (-CH2 ben).  1H NMR 
400 MHz: (DMSO-d6, δ ppm): 0.89 (m, 6H, -CH3), 1.33 (m, 6H, -CH2), 1.61 (m, 2H, 
-CH2), 2.32 (m, 1H, -CH), 3.20 (s, 3H, -CH3), 3.86 (s, 1H, -CH), 7.78 (s, broad, 1H,-
NH), 9.93 (s, broad, 1H,-NH), 11.66 (s, broad, 1H,-NH). 13C NMR 400 MHz: 
(DMSO-d6, δ ppm): 13.70, 20.15, 34.56, 43.76, 173.2 Mass: [m/z (%)], M. Wt.: 
298. Elemental analysis, Calculated: C, 52.32; H, 7.43; N, 18.78 Found: C, 52.22; 
H, 7.49; N, 18.85 
N'-(2-hydrazinylthiazol-4-yl)-2-propylpentanehydrazide (DPB-70) 
IR (KBr) cm-1: 3455 (N-H str), 2947 (-CH3 str.), 2952 (-CH2 str.), 2849 (-CH3 str.), 
1641 (-CONH), 1625 (N-H bending), 1452 (-CH3 ben), 1375 (-CH2 ben). Mass: [m/z 
(%)], M. Wt.: 271. Elemental analysis, Calculated: C, 48.68; H, 7.80; N, 25.81 
Found: C, 48.65; H, 7.77; N, 25.89 
N'-(2-(diphenylamino)thiazol-4-yl)-2-propylpentanehydrazide (DPB-71) 
IR (KBr) cm-1: 3445 (N-H str), 2951 (-CH3 str.), 2945 (-CH2 str.), 2852 (-CH3 str.), 
1658 (-CONH), 1630 (N-H bending), 1458 (-CH3 ben), 1371 (-CH2 ben), 3011 (=C-
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H, str), 3045 (Ar, C-H, str), 1529 (Ar, C=C, str). Mass: [m/z (%)], M. Wt.: 408. 
Elemental analysis, Calculated: C, 67.61; H, 6.91; N, 13.71 Found: C, 67.66; H, 
6.85; N, 13.68 
N'-(2-(benzamido)thiazol-4-yl)-2-propylpentanehydrazide (DPB-72) 
IR (KBr) cm-1: 3440 (N-H str), 2959 (-CH3 str.), 2947 (-CH2 str.), 2859 (-CH3 str.), 
1648 (-CONH), 1636 (N-H bending), 1457 (-CH3 ben), 1372 (-CH2 ben), 3018 (=C-
H, str), 3055 (Ar, C-H, str), 1535 (Ar, C=C, str). Mass: [m/z (%)], M. Wt.: 360. 
Elemental analysis, Calculated: C, 59.97; H, 6.71; N, 15.54 Found: C, 59.95; H, 
6.69; N, 15.50 
N'-(2-(4-methylbenzamido)thiazol-4-yl)-2-propylpentanehydrazide (DPB-73) 
IR (KBr) cm-1: 3441 (N-H str), 2962 (-CH3 str.), 2941 (-CH2 str.), 2862 (-CH3 str.), 
1642 (-CONH), 1639 (N-H bending), 1462 (-CH3 ben), 1370 (-CH2 ben), 3022 (=C-
H, str), 3053 (Ar, C-H, str), 1545 (Ar, C=C, str). Mass: [m/z (%)], M. Wt.: 374. 
Elemental analysis, Calculated: C, 60.94; H, 7.00; N, 14.96 Found: C, 60.97; H, 
7.03; N, 14.98 
N'-(2-(3-methylbenzamido)thiazol-4-yl)-2-propylpentanehydrazide (DPB-74) 
IR (KBr) cm-1: 3439 (N-H str), 2955 (-CH3 str.), 2953 (-CH2 str.), 2849 (-CH3 str.), 
1649 (-CONH), 1645 (N-H bending), 1478 (-CH3 ben), 1375 (-CH2 ben), 3010 (=C-
H, str), 3049 (Ar, C-H, str), 1549 (Ar, C=C, str). Mass: [m/z (%)], M. Wt.: 374. 
Elemental analysis, Calculated: C, 60.94; H, 7.00; N, 14.96 Found: C, 60.98; H, 
7.04; N, 14.92 
N'-(2-(2-methylbenzamido)thiazol-4-yl)-2-propylpentanehydrazide (DPB-75) 
IR (KBr) cm-1: 3446 (N-H str), 2956 (-CH3 str.), 2951 (-CH2 str.), 2855 (-CH3 str.), 
1647 (-CONH), 1641 (N-H bending), 1470 (-CH3 ben), 1369 (-CH2 ben), 3015 (=C-
H, str), 3050 (Ar, C-H, str), 1552 (Ar, C=C, str). Mass: [m/z (%)], M. Wt.: 374. 
Elemental analysis, Calculated: C, 60.94; H, 7.00; N, 14.96 Found: C, 60.95; H, 
7.05; N, 14.98 
N'-(2-(4-chlorobenzamido)thiazol-4-yl)-2-propylpentanehydrazide (DPB-76) 
IR (KBr) cm-1: 3442 (N-H str), 2958 (-CH3 str.), 2956 (-CH2 str.), 2849 (-CH3 str.), 
1648 (-CONH), 1647 (N-H bending), 1465 (-CH3 ben), 1371 (-CH2 ben), 3016 (=C-
H, str), 3051 (Ar, C-H, str), 1549 (Ar, C=C, str), 742 (C-Cl). Mass: [m/z (%)], M. 
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Wt.: 394. Elemental analysis, Calculated: C, 54.74; H, 5.87; N, 14.19 Found: C, 
54.76; H, 5.89; N, 14.22 
N'-(2-(3-chlorobenzamido)thiazol-4-yl)-2-propylpentanehydrazide (DPB-77) 
IR (KBr) cm-1: 3441 (N-H str), 2959 (-CH3 str.), 2957 (-CH2 str.), 2852 (-CH3 str.), 
1656 (-CONH), 1650 (N-H bending), 1462 (-CH3 ben), 1378 (-CH2 ben), 3010 (=C-
H, str), 3056 (Ar, C-H, str), 1552 (Ar, C=C, str), 748 (C-Cl). Mass: [m/z (%)], M. 
Wt.: 394. Elemental analysis, Calculated: C, 54.74; H, 5.87; N, 14.19 Found: C, 
54.70; H, 5.83; N, 14.20 
N'-(2-(2-chlorobenzamido)thiazol-4-yl)-2-propylpentanehydrazide (DPB-78) 
IR (KBr) cm-1: 3448 (N-H str), 2958 (-CH3 str.), 2953 (-CH2 str.), 2848 (-CH3 str.), 
1648 (-CONH), 1644 (N-H bending), 1460 (-CH3 ben), 1376 (-CH2 ben), 3021 (=C-
H, str), 3041 (Ar, C-H, str), 1549 (Ar, C=C, str), 747 (C-Cl). Mass: [m/z (%)], M. 
Wt.: 394. Elemental analysis, Calculated: C, 54.74; H, 5.87; N, 14.19 Found: C, 
54.69; H, 5.84; N, 14.23 
N'-(2-(4-nitrobenzamido)thiazol-4-yl)-2-propylpentanehydrazide (DPB-79) 
IR (KBr) cm-1: 3452 (N-H str), 2955 (-CH3 str.), 2954 (-CH2 str.), 2847 (-CH3 str.), 
1648 (-CONH), 1640 (N-H bending), 1463 (-CH3 ben), 1374 (-CH2 ben), 3025 (=C-
H, str), 3047 (Ar, C-H, str), 1556 (Ar, C=C, str). Mass: [m/z (%)], M. Wt.: 405. 
Elemental analysis, Calculated: C, 53.32; H, 5.72; N, 17.27 Found: C, 53.35; H, 
5.70; N, 17.30 
N'-(2-(3-nitrobenzamido)thiazol-4-yl)-2-propylpentanehydrazide (DPB-80) 
IR (KBr) cm-1: 3442 (N-H str), 2958 (-CH3 str.), 2956 (-CH2 str.), 2849 (-CH3 str.), 
1652 (-CONH), 1647 (N-H bending), 1461 (-CH3 ben), 1370 (-CH2 ben), 3016 (=C-
H, str), 3059 (Ar, C-H, str), 1549 (Ar, C=C, str). Mass: [m/z (%)], M. Wt.: 405. 
Elemental analysis, Calculated: C, 53.32; H, 5.72; N, 17.27 Found: C, 53.30; H, 
5.71; N, 17.29 
N'-(2-(2-phenylacetamido)thiazol-4-yl)-2-propylpentanehydrazide (DPB-81) 
IR (KBr) cm-1: 3452 (N-H str), 2955 (-CH3 str.), 2951 (-CH2 str.), 2856 (-CH3 str.), 
1640 (-CONH), 1644 (N-H bending), 1461 (-CH3 ben), 1375 (-CH2 ben), 3022 (=C-
H, str), 3045 (Ar, C-H, str), 1549 (Ar, C=C, str). Mass: [m/z (%)], M. Wt.: 374. 
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Elemental analysis, Calculated: C, 60.94; H, 7.00; N, 14.96 Found: C, 60.95; H, 
7.03; N, 14.98 
4.17  CONCLUSION 
 
In conclusion, several novel valproate containing thiazole derivatives for biological 
activity were synthesized. The reaction of valproate with hydrazine hydrate afforded 
the 2-propyl pentanohydrazide, which on reaction with chloroacetyl chloride yielded 
the N'-(2-chloroacetyl)-2-propyl pentanehydrazide. The desired thiazole derivatives 
had been synthesized by the reaction of thiourea with N'-(2-chloroacetyl)-2-propyl 
pentanehydrazide. All the newly synthesized compounds were well characterized by 
spectroscopy techniques.  
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IR spectrum of N'-(2-(methylamino)thiazol-4-yl)-2-propylpentanehydrazide 
(DPB-68) 
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5.1      INTRODUCTION 
 
The present chapter deals with the preliminary biological screening results of DPB 1 to 
DPB 26  compounds synthesized during the course of research work, which are 
heterocycles like N-(2-oxo-2H-chromen-4-yl)-2-(substituted amine -1-yl)acetamide 
derivatives. In the current chapter, biological aspects of anti tubercular screening were 
described along with the activity protocols and activity data obtained by preliminary 
screening In vitro. Finally on the screening results a brief discussion is also narrated. 
 
The anti tubercular screening of all the synthesized compounds of DPB 1 to 26 series was 
carried out at Tuberculosis Antimicrobial Acquisition and Coordinating Facility 
(TAACF), Alabama, USA. 
 
5.2 PROCEDURE FOR THE RESAZURIN MIC ASSAY 
 
The resazurin MIC assay, developed by Collins and Franzblau (1997), is a colorimetric 
assay used to test compounds for antimycobacterial activity. A color change from blue to 
pink is observed when growth occurs. Compounds are initially tested at a single point 
concentration of 10 μg/ml against Mycobacteruim tuberculosis H37Rv (H37Rv), 
obtained from Colorado State University, Fort Collins, CO. If compounds are active at 
the 10 μg/ml level, they are further tested in an MIC assay at 8 concentrations in a dose 
range between 10 to 0.078 μg/ml.  
 
 Preparation of Test Compounds  
 
The test compounds were placed in a -20 °C freezer. The day of the experiment, one vial 
from each compound is reconstituted using the supplier’s recommended solvent to 
achieve a stock concentration of 3.2 mg/ml.  
 
 Inoculum Preparation  
 
H37Rv was grown in Middlebrook 7H9 broth medium (7H9 medium) supplemented with 
0.2% (v/v) glycerol, 10% (v/v) ADC (albumin, dextrose, catalase), and 0.05% (v/v) 
Tween 80. The bacteria were inoculated in 50 ml of 7H9 medium in 1 liter roller bottles 
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that were placed on a roller bottle apparatus in an ambient 37 °C incubator. When the 
cells reach an OD600 of 0.150 (equivalent to ~1.5 x 107 CFU/ml), they were diluted 200-
fold in 7H9 medium.  
 
 Single Point Concentration Procedure  
 
The procedure is the same as that used for the MIC procedure described below, but only 
the first 2 fold dilution was made that reduces the stock solution to 1.6 mg/ml. An 
additional 1:10 dilution was made in water (see Step 3 below) which reduces the stock 
solution further to 0.16 mg/ml. Addition of 6.25 μl of the 1:10 dilution to the wells in a 
final volume of 100 μl gave rise to a concentration equivalent to 10 μg/ml (see Step 2 
below).  
 
 MIC Procedure  
 
1.  20 μl of the 3.2 mg/ml test compound was added to a 96-well microtiter plate.  
2.  2-fold dilutions were made by the addition of 20 μl of diluent.  
Expected final Test Compound = 3.2 mg/ml 
dose level (μg/ml) 
 
10  1st dilution of 8 = 1.6 mg/ml 
 
 5  2nd dilution of 8 = 0.8 mg/ml 
 
 2.5  3rd dilution of 8 = 0.4 mg/ml 
 
 1.25  4th dilution of 8 = 0.2 mg/ml 
 
 0.625  5th dilution of 8 = 0.1 mg/ml 
 
 0.312  6th dilution of 8 = 0.05 mg/ml 
 
 0.156  7th dilution of 8 = 0.025 mg/ml 
 
 0.078  8th dilution of 8 = 0.0125 mg/ml 
3.  Each dilution was further diluted 1:10 in sterile water (10 μl of dilution to 90 μl of 
sterile water). Note: The additional 10-fold dilution in water was required when 
DMSO was used as solvent to minimize toxicity to the bacteria. For uniformity in 
Dilute 1:2
Dilute 1:2
Dilute 1:2
Dilute 1:2
Dilute 1:2
Dilute 1:2
Dilute 1:2
Dilute 1:2
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the assay procedure, this dilution step was used even if water or other solvents are 
used.  
4.  6.25 μl of each dilution is transferred to duplicate 96-well test plates.  
5.  93.75 μl of the cell suspension (~ 104 bacteria) in 7H9 medium was added to the 
test plates.  
6.  Positive, negative, sterility and resazurin controls ware tested.  
a.  Positive controls include: Rifampicin and Isoniazid  
b.  Negative controls include:  
i. Cell culture with solvent and water  
ii. Cell culture only  
c.  Sterility controls include:  
i. Media only  
ii. Media with solvent and water  
d.  Resazurin control includes one plate containing the diluted compounds 
with resazurin only. No bacterial suspension is added. This control plate is 
needed to verify whether the compound reacts with resazurin that could 
possibly elicit fluorescence.  
7.  The 96 well test plates were incubated in an ambient 37 ºC incubator for 6 days.  
8.  After the 6 day incubation, 5 μl of a 0.05% sterile resazurin solution was added to 
each well of the 96-well plate. The plates were placed in an ambient 37 ºC 
incubator for 2 days.  
9.  After the 2 day incubation, a visual evaluation and fluorimetric read-out was 
performed.  The results were expressed as μg/ml (visual evaluation) and as IC50 
and IC90 (fluoremetric readout)  
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TABLE-1 – IC50 VALUE OF NEWLY    SYNTHESIZED COMPOUNDS 
CHAPTER-1 
 
Compound ID Structure Solvent Results (µg/ml) 
DPB-1 
O O
HN O
N
 
DMSO >10 
DPB-2 
 
DMSO >10 
DPB-3 
 
DMSO >10 
DPB-4 
 
DMSO >10 
DPB-5 
 
DMSO >10 
DPB-6 
 
DMSO >10 
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DPB-7 
 
DMSO >10 
DPB-8 
 
DMSO >10 
DPB-9 
 
DMSO >10 
DPB-10 
 
DMSO >10 
DPB-11 
 
DMSO >10 
DPB-12 
 
DMSO >10 
DPB-13 
 
DMSO >10 
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DPB-14 
 
DMSO >10 
DPB-15 
 
DMSO >10 
DPB-16 
 
DMSO >10 
DPB-17 
 
DMSO >10 
DPB-19 
 
DMSO >10 
DPB-18 
 
DMSO >10 
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DPB-20 
 
DMSO >10 
DPB-21 
 
DMSO >10 
DPB-22 
 
DMSO >10 
DPB-23 
 
DMSO >10 
DPB-24 
 
DMSO >10 
DPB-25 
 
DMSO >10 
 
Chapter-5                                    Biological evaluation of synthesized compounds 
 
Department of Chemistry, Saurashtra University, Rajkot   150 
 
DPB-26 
 
DMSO >10 
Rifampin DMSO 0.0125 
Isoniazid DMSO 0.063 
 
 
Reference:  
 
Collins, L. A. and S. G. Franzblau. Microplate Alamar Blue Assay versus BACTEC 460 
System for High-Throughput Screening of Compounds against Mycobacterium 
tuberculosis and Mycobacterium avium. Antimicrobial Agents and Chemotherapy, 
41:1004-1009 (1997). 
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The work represented in the thesis entitled “STUDIES ON DIVERSED 
HETEROCYCLIC CHEMICAL ENTITIES & THEIR APPLICATION” is divided into 
five chapters which can be summarized as under. 
Chapter-1 relates with the introduction of oxygen heterocycle – coumarin. It deals with 
synthesis of 26 new molecules derived from 4-amino coumarin to arrive at variously 
functionalized N-(2-oxo-2H-chromen-4-yl)-2-(substituted amine -1-yl)acetamide 
derivatives. The chapter covers reaction mechanism, IR, 1H NMR, 13C NMR, Mass 
spectral and other physical data to support the structure elucidation. 
Chapter-2 deals with the imidazo[1,2-a]pyridine derivatives. In this chapter we have 
developed a novel, rapid and efficient methodology for the synthesis of highly 
functionalized imidazoles and thiazoles. This process involves protection and 
deprotection of amine functionality by BOC. The deprotection of amine group has been 
carried out using SiO2 under microwave irradiation with short reaction time and afforded 
products with high chemical purity. The main advantage of this process is silica gel, 
which is inexpensive and non-toxic material and reusable after reaction. The process 
delivers very high yields of the products for biological interest.  The chapter covers 
reaction mechanism, IR, 1H NMR, 13C NMR, Mass spectral and other physical data to 
support the structure elucidation. 
Chapter-3 covers an introduction of oxadiazole. It deals with synthesis of 25 new 
molecules derived from 1,3,4-oxadiazole coupled with various primary and secondary 
amines. The process delivers very high yields of the products for biological interest. The 
chapter covers reaction mechanism, IR, 1H NMR, 13C NMR, Mass spectral and other 
physical data to support the structure elucidation. 
Chapter-4 is an effort to modify known antiepileptic drug valproic acid to convert into 
various analogs, in order to explore other biological activities. Total 15 compounds are 
synthesized. The new molecules derived from condensation of (2-chloroacetyl)-2-
propylpentanehydrazide with thiourea afforded 5 novel derivatives. Further, (2-
aminothiazol-4-yl)-2-propylpentanehydrazide react with substituted acid chlorides 
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afforded 10 novel derivatives. The synthesized compounds were well characterized by 
IR, 1H and 13C NMR and Mass spectrometry. 
Chapter-5, we have demonstrates the biological activity of newly synthesized N-(2-oxo-
2H-chromen-4-yl)-2-(substituted amine-1-yl)acetamide. The biological study of the 
synthesized compounds revels that the tested compounds were moderate to good against 
Mycobacterium tuberculosis H37Rv. The biological activities of remaining compounds 
are under study.   
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PAPER 
 
1. Synthesis of some novel benzofuran-2-yl(4,5-dihyro-3,5-substituted 
diphenylpyrazol-1-yl) methanones and studies on the antiproliferative 
effects and reversal of multidrug resistance of human MDR1-gene 
transfected mouse lymphoma cells in vitro.  
 
Shrey Parekh, Dhairya Bhavsar, Mahesh Savant, Shailesh Thakrar, Abhay 
Bavishi, Manisha Parmar, Hardev Vala, Ashish Radadiya, Nilay Pandya, Juliana 
Serly, Joseph Molnár and Anamik Shah*, European Journal of Medicinal 
Chemistry, 46(2011) 1942-1948. 
 
2. Synthesis and biological evaluation of 4-Styrylcoumarin derivatives as 
inhibitors of TNF-α and IL-6 with anti-tubercular activity" has been 
received by Bioorganic & Medicinal Chemistry Letters.  
 
Kuldip Upadhyay, Abhay Bavishi, Shailesh Thakrar, Ashish Radadiya, 
Hardevsinh Vala, Shrey Parekh, Dhairya Bhavsar, Mahesh Savant, Manisha 
Parmar, Priti Adlakha and Anamik Shah*, Bioorganic and Medicinal Chemistry 
Letters, Doi:10.1016/j.bmcl.2011.02.016.  
3. Synthesis and In Vitro anti-HIV Activity of N-1,3-benzo[d]thiazol-2-yl-2-(2-
oxo-2H-chromen-4-yl) Acetamide Derivatives using MTT method.  
 
Dhairya Bhavsar, Jalpa Trivedi, Shrey Parekh, Mahesh Savant, Shailesh 
Thakrar, Abhay Bavishi, Ashish Radadiya, Hardev Vala, Manisha Parmar, 
Roberta Loddo, Anamik Shah*, Bioorganic & Medicinal Chemistry Letters. 
(Accepted) 
 
4. An efficient synthesis of highly functionalized imidazoles and thiazoles using 
microwave irradiation 
 
Dhairya Bhavsar, Shrey Parekh, Jignesh Lunagariya, Abhay Bavishi, Shailesh 
Thakrar, Manisha Parmar, Hardevsinh Vala, Mahesh Savant, Anamik Shah*, 
Synthetic communication, (Under Review) 
5. An efficient and rapid synthesis of highly functionalized novel symmetric 
1,4-dihydropyridines using glacial acetic acid as a solvent. 
 
Shailesh Thakrar, Abhay Bavishi, Dhairya Bhavsar, Shrey Parekh, Hardev Vala, 
Ashish Radadiya, Manisha Parmar, Mahesh Savant, Nilay Pandya and Anamik 
Shah*, Synthetic communication, (Accepted) 
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6. Diversity oriented design of various hydrazides and their in vitro evaluation 
against Mycobacterium tuberculosis H37Rv strains.  
 
Atul Manvar, Abhay Bavishi, Shailesh Thakrar, Dhairya Bhavsar, Hardev Vala, 
Anamik Shah*, Bioorganic & Medicinal Chemistry Letters (Under Review)  
 
7. Synthesis and Biological evaluation of 1-[2,4-dimethyl-5-(5-aryl-1,3,4-
oxadiazol-2-yl)-1H-pyrrol-3-yl] ethanones as potent Anti-tubercular and 
Antibacterial agents.  
 
Kuldip Upadhyay, Abhay Bavishi, Ashish Radadiya, Shailesh Thakrar, 
Hardevsinh Vala, Shrey Parekh, Dhairya Bhavsar, Mahesh Savant, Manisha 
Parmar, Kena Raval, Chetna Rajyaguru, Anamik Shah*, Bioorganic & Medicinal 
Chemistry Letters (Under Review) 
 
8. In vitro anticancer evaluation against different cell lines of molecularly 
diverse N-substituted oxyindoles.  
 
Abhay Bavishi, Atul Manvar, Ashish Radadiya, Shailesh Thakrar, Hardevsinh 
Vala, Shrey Parekh, Manisha Parmar, Dhairya Bhavsar, Mahesh Savant, Priti 
Adlakha, Manu Jaggi and Anamik Shah*, European Journal of Medicinal 
Chemistry (Under Review) 
 
9. An Efficient Microwave assisted one pot synthesis of novel 2-amino 3-cyano 
pyridine derivatives using Two Reusable Solid Acids as Catalysts.  
 
Shailesh Thakrar, Abhay Bavishi, Dhairya Bhavsar, Shrey Parekh, Hardevsinh 
Vala, Ashish Radadiya, Mahesh Savant, Manisha Parmar, Nilay Pandya and 
Anamik Shah*, Tetrahedron Letters (Under Review) 
 
10. Microwave assisted rapid Synthesis of novel 1,5-benzodiazepines derivatives 
as potent antimicrobial agent.  
 
Shailesh Thakrar, Abhay Bavishi, Shrey Parekh, Dhairya Bhavsar, Hardevsinh 
Vala, Ashish Radadiya, Manisha Parmar, Nilay Pandya and Anamik Shah*, 
Journal of heterocyclic chemistry (Under Review) 
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PRESENTATION 
 
 A Simple and efficient cleavage of N-Boc using silica under microwave 
irritation 
 
Dhairya Bhavsar, Shrey Parekh, Sailesh Thakrar and Anamik Shah* 
Poster Presented at 15th ISCB International conference “Bridging gaps in discovery and 
development: Chemical & biological science for affordable health, wellness & 
sustainbility” on Saurashtra University, Rajkot on 4-7th Feb. 2011. 
 Synthesis and anti-HIV Activity of N-1, 3-benzo[d]thiazol-2-yl-2-(2-oxo-2H-
chromen-4-yl) acetamides 
 
            Dhairya Bhavsar, Jalpa Trivedi and Anamik Shah* 
Poster Presented at 14th ISCB International conference “International conference on 
chemical biology for discovery: perspectives and Challenges” on CDRI, Lucknow on 
15-18th Jan., 2010. 
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1. ISCB Conference “Bridging gaps in discovery and development: Chemical & 
biological science for affordable health, wellness & sustainbility” at Saurahtra 
University, Rajkot on 4-7th Feb., 2011.  
 
2. ISCB Conference “International conference on chemical biology for discovery: 
perspectives and Challenges” at CDRI, Lucknow on 15-18th Jan., 2010. 
 
3. “International Seminar on Recent Developments in Structure and Ligandbased 
Drug Design” jointly organized by Schrodinger LLC, USA; National Facility for 
Drug Discovery through New Chemicals Entities Development & Instrumentation 
support to Small Manufacturing Pharma Enterprises and DSTFIST, UGC-SAP & 
DST-DPRP Funded Department of Chemistry, Saurashtra University, Rajkot on 
23rd, December, 2009. 
 
4. “National seminar on Alternative Synthetic Strategies for Drugs & Drug 
Intermediates” at Institute of Pharmacy, Nirma University, Ahmedabad on 13th 
November, 2009. 
 
5. “Two Days National Workshop on Patents & Intellectual Property Rights 
Related Updates” Sponsored by TIFAC & GUJCOST and Organized by DST-
FIST, UGC-SAP & DST-DPRP Funded Department of Chemistry, Saurashtra 
University, Rajkot on 19-20th  September, 2009. 
 
6. DST-FIST, UGC (SAP) supported and GUJCOST Sponsored “National 
Conference on Selected Topics in Spectroscopy and Stereochemistry” organized 
by the Department of Chemistry, Saurashtra University, Rajkot on 18-20th March, 
2009.  
 
7. National seminar on “Recent Advances in Chemical Sciences & an Approach to 
Green Chemistry”, Rajkot on October, 2006.  
 
8. National workshop on “E-resources in Chemical Synthsis and Natural 
Products”, Rajkot on March, 2006 
